+关注
Darious
暂无个人介绍
IP属地:未知
187
关注
45
粉丝
0
主题
0
勋章
主贴
热门
Darious
2021-08-20
Great
The Stock Market Is Dropping Again. What’s Behind Its Worst Slump Since July.<blockquote>股市又在下跌了。自7月以来最严重的暴跌背后是什么?</blockquote>
Darious
2021-08-20
Great
抱歉,原内容已删除
Darious
2021-08-18
Great
Tencent second-quarter profit rises 29%<blockquote>腾讯控股第二季度利润增长29%</blockquote>
Darious
2021-08-16
RIP
抱歉,原内容已删除
Darious
2021-08-15
[财迷]
抱歉,原内容已删除
Darious
2021-08-15
Great
抱歉,原内容已删除
Darious
2021-08-12
Great
抱歉,原内容已删除
Darious
2021-08-11
Great
抱歉,原内容已删除
Darious
2021-08-10
Great
抱歉,原内容已删除
Darious
2021-08-09
Great
抱歉,原内容已删除
Darious
2021-08-07
Great
抱歉,原内容已删除
Darious
2021-08-06
Great
抱歉,原内容已删除
Darious
2021-08-04
Great
3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>
Darious
2021-08-02
Nice
抱歉,原内容已删除
Darious
2021-07-27
Nice
7 Stocks To Watch For July 27, 2021<blockquote>2021年7月27日值得关注的7只股票</blockquote>
Darious
2021-07-25
Great
抱歉,原内容已删除
Darious
2021-07-24
Great
抱歉,原内容已删除
Darious
2021-07-23
Great
抱歉,原内容已删除
Darious
2021-07-22
No....
U.S. weekly jobless claims total 419,000 vs. 350,000 estimate<blockquote>美国每周初请失业金人数总计41.9万人,预估为35万人</blockquote>
Darious
2021-07-16
Like
抱歉,原内容已删除
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3570801892131113","uuid":"3570801892131113","gmtCreate":1607709040008,"gmtModify":1618192400291,"name":"Darious","pinyin":"darious","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":45,"headSize":187,"tweetSize":61,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖(非转发)","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.71%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.71%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":836320011,"gmtCreate":1629457339633,"gmtModify":1633684717382,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570801892131113","idStr":"3570801892131113"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/836320011","repostId":"1169769842","repostType":4,"repost":{"id":"1169769842","kind":"news","pubTimestamp":1629449461,"share":"https://www.laohu8.com/m/news/1169769842?lang=zh_CN&edition=full","pubTime":"2021-08-20 16:51","market":"us","language":"en","title":"The Stock Market Is Dropping Again. What’s Behind Its Worst Slump Since July.<blockquote>股市又在下跌了。自7月以来最严重的暴跌背后是什么?</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1169769842","media":"Barron's","summary":"The S&P 500 is on pace for its worst three-day drop since July. Is the sky starting to fall?\nIt sure","content":"<p>The <a href=\"https://laohu8.com/S/.SPX\">S&P 500</a> is on pace for its worst three-day drop since July. Is the sky starting to fall?</p><p><blockquote>The<a href=\"https://laohu8.com/S/.SPX\">标普500</a>即将出现自7月份以来最严重的三天跌幅。天要塌下来了吗?</blockquote></p><p> It sure does look ugly out there. S&P 500 futures have declined 0.6% Thursday morning, indicating an opening loss of around 28 points, or 0.6%, for the index. The Dow Jones Industrial Average (<a href=\"https://laohu8.com/S/.DJI\">DJIA</a>), meanwhile, could be headed for a 237 point, or 0.7%, decline, per futures markets.</p><p><blockquote>外面看起来确实很丑。标普500期货周四上午下跌0.6%,表明该指数开盘下跌约28点,即0.6%。道琼斯工业平均指数(<a href=\"https://laohu8.com/S/.DJI\">道琼斯</a>与此同时,根据期货市场的数据,该指数可能会下跌237点,即0.7%。</blockquote></p><p> If the losses hold, it would be the S&P 500’s third consecutive drop, the index’s longest losing streak since the three-day losing streak that ended on July 19. At this pace, the index would shed around 2.4% over a three-day period, also the worst since that July tumble.</p><p><blockquote>如果跌势持续,这将是标普500连续第三次下跌,这是该指数自7月19日结束三日连跌以来最长的连跌。按照这个速度,该指数将在三天内下跌约2.4%,这也是自7月份暴跌以来最严重的一次。</blockquote></p><p> If you want reasons for the decline, well, there are plenty. Taper fears are at the top of the list, despite the fact that the Fed has been about as transparent about the fact that it will end its bond-buying program soon as it’s possible to be. (Can a big article in The Wall Street Journal with the headline “Fed Officials Weigh Ending Asset Purchases by Mid-2022” be any more obvious?)</p><p><blockquote>如果你想知道下降的原因,那么,有很多。尽管美联储一直尽可能透明地表示将尽快结束债券购买计划,但对缩减购债计划的担忧仍排在首位。(《华尔街日报》上一篇标题为“美联储官员权衡在2022年年中之前结束资产购买”的大文章还能更明显吗?)</blockquote></p><p> But history shows that markets react to changes in monetary policy—even when they know the change is coming, says Bleakley Advisory Group’s Peter Boockvar. “[We] have to be reminded of how stocks responded to EVERY SINGLE change in Fed policy towards tightening since 2010,” he writes. “Outside of the August 2015 selloff related to the Chinese yuan modest devaluation and the Covid induced crash, every notable correction in stocks surrounded a change Fed policy toward tightening.”</p><p><blockquote>但布莱克利咨询集团的彼得·布克瓦尔表示,历史表明,市场会对货币政策的变化做出反应——即使他们知道变化即将到来。“[我们]必须提醒股市对2010年以来美联储紧缩政策的每一次变化的反应,”他写道。“除了2015年8月与人民币小幅贬值和新冠疫情引发的崩盘相关的抛售之外,股市的每一次显着调整都围绕着美联储紧缩政策的变化。”</blockquote></p><p> Covid concerns continue to rise, whether its cases forcing shutdowns in <a href=\"https://laohu8.com/S/NGD\">New</a> Zealand or reports that the vaccines aren’t as effective against the Delta variant as originally thought. Again, none of this is terribly new, but then again, the market chooses when it wants to react, not folks with a keyboard.</p><p><blockquote>对新冠病毒的担忧持续上升,无论其病例是否迫使工厂关闭<a href=\"https://laohu8.com/S/NGD\">新的</a>新西兰或报告称,疫苗对德尔塔变异毒株的效果并不像最初想象的那样。再说一次,这些都不是什么新鲜事,但话说回来,市场会选择何时做出反应,而不是拿着键盘的人。</blockquote></p><p> If you listen to the thrum of the Street, though, you get the sense that the market has been due for a correction. There’s some truth to that. The S&P 500 has been more than 8% above its 200-day moving average for 198 days, the longest in 40 years and among the five longest stretches in history. These streaks are usually followed by a couple of months of choppy trading, with a median gain of just 0.3% over the following two months. “By the time it reached the current length, other super-strong trends saw buyers take a break,” writes Sundial Capital Research’s Jason Goepfert.</p><p><blockquote>不过,如果你听听街上的喧闹声,你会觉得市场已经到了调整的时候了。这有一定的道理。标普500已经有198天比200日移动平均线高出8%以上,这是40年来最长的一次,也是历史上最长的五次之一。这些连涨之后通常会出现几个月的波动交易,接下来两个月的中值涨幅仅为0.3%。Sundial Capital Research的Jason Goepfert写道:“当它达到目前的长度时,其他超级强劲的趋势让买家休息一下。”</blockquote></p><p> Of course, it might just be August, says DataTrek’s Nicholas Colas. He notes that the S&P 500 typically has one 1% up or down move every week since 1957, but has had just three during the first seven weeks of the third quarter. August, because of its low volume and history of higher volatility would be a good time to catch up.</p><p><blockquote>DataTrek的尼古拉斯·科拉斯(Nicholas Colas)表示,当然,可能只是八月。他指出,自1957年以来,标普500通常每周都会上涨或下跌1%,但第三季度前七周仅上涨或下跌3次。八月,由于其交易量较低且波动性较高的历史,将是追赶的好时机。</blockquote></p><p> That’s especially true with stocks starting to move together again. “[As] much as we like U.S. equities, we have to respect both the tape (suddenly higher correlations) and seasonality (late August volatility),” Colas writes. “Both tell us to be cautious over the next 2-3 weeks.”</p><p><blockquote>当股市再次开始同步波动时尤其如此。科拉斯写道:“尽管我们非常喜欢美国股市,但我们必须尊重磁带(相关性突然上升)和季节性(八月下旬的波动性)。”“两者都告诉我们在未来2-3周内要保持谨慎。”</blockquote></p><p> So buckle up. Whatever the reason, it’s chop time for U.S. stock markets.</p><p><blockquote>所以系好安全带。不管是什么原因,现在是美国股市下跌的时候了。</blockquote></p><p></p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Stock Market Is Dropping Again. What’s Behind Its Worst Slump Since July.<blockquote>股市又在下跌了。自7月以来最严重的暴跌背后是什么?</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Stock Market Is Dropping Again. What’s Behind Its Worst Slump Since July.<blockquote>股市又在下跌了。自7月以来最严重的暴跌背后是什么?</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barron's</strong><span class=\"h-time small\">2021-08-20 16:51</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The <a href=\"https://laohu8.com/S/.SPX\">S&P 500</a> is on pace for its worst three-day drop since July. Is the sky starting to fall?</p><p><blockquote>The<a href=\"https://laohu8.com/S/.SPX\">标普500</a>即将出现自7月份以来最严重的三天跌幅。天要塌下来了吗?</blockquote></p><p> It sure does look ugly out there. S&P 500 futures have declined 0.6% Thursday morning, indicating an opening loss of around 28 points, or 0.6%, for the index. The Dow Jones Industrial Average (<a href=\"https://laohu8.com/S/.DJI\">DJIA</a>), meanwhile, could be headed for a 237 point, or 0.7%, decline, per futures markets.</p><p><blockquote>外面看起来确实很丑。标普500期货周四上午下跌0.6%,表明该指数开盘下跌约28点,即0.6%。道琼斯工业平均指数(<a href=\"https://laohu8.com/S/.DJI\">道琼斯</a>与此同时,根据期货市场的数据,该指数可能会下跌237点,即0.7%。</blockquote></p><p> If the losses hold, it would be the S&P 500’s third consecutive drop, the index’s longest losing streak since the three-day losing streak that ended on July 19. At this pace, the index would shed around 2.4% over a three-day period, also the worst since that July tumble.</p><p><blockquote>如果跌势持续,这将是标普500连续第三次下跌,这是该指数自7月19日结束三日连跌以来最长的连跌。按照这个速度,该指数将在三天内下跌约2.4%,这也是自7月份暴跌以来最严重的一次。</blockquote></p><p> If you want reasons for the decline, well, there are plenty. Taper fears are at the top of the list, despite the fact that the Fed has been about as transparent about the fact that it will end its bond-buying program soon as it’s possible to be. (Can a big article in The Wall Street Journal with the headline “Fed Officials Weigh Ending Asset Purchases by Mid-2022” be any more obvious?)</p><p><blockquote>如果你想知道下降的原因,那么,有很多。尽管美联储一直尽可能透明地表示将尽快结束债券购买计划,但对缩减购债计划的担忧仍排在首位。(《华尔街日报》上一篇标题为“美联储官员权衡在2022年年中之前结束资产购买”的大文章还能更明显吗?)</blockquote></p><p> But history shows that markets react to changes in monetary policy—even when they know the change is coming, says Bleakley Advisory Group’s Peter Boockvar. “[We] have to be reminded of how stocks responded to EVERY SINGLE change in Fed policy towards tightening since 2010,” he writes. “Outside of the August 2015 selloff related to the Chinese yuan modest devaluation and the Covid induced crash, every notable correction in stocks surrounded a change Fed policy toward tightening.”</p><p><blockquote>但布莱克利咨询集团的彼得·布克瓦尔表示,历史表明,市场会对货币政策的变化做出反应——即使他们知道变化即将到来。“[我们]必须提醒股市对2010年以来美联储紧缩政策的每一次变化的反应,”他写道。“除了2015年8月与人民币小幅贬值和新冠疫情引发的崩盘相关的抛售之外,股市的每一次显着调整都围绕着美联储紧缩政策的变化。”</blockquote></p><p> Covid concerns continue to rise, whether its cases forcing shutdowns in <a href=\"https://laohu8.com/S/NGD\">New</a> Zealand or reports that the vaccines aren’t as effective against the Delta variant as originally thought. Again, none of this is terribly new, but then again, the market chooses when it wants to react, not folks with a keyboard.</p><p><blockquote>对新冠病毒的担忧持续上升,无论其病例是否迫使工厂关闭<a href=\"https://laohu8.com/S/NGD\">新的</a>新西兰或报告称,疫苗对德尔塔变异毒株的效果并不像最初想象的那样。再说一次,这些都不是什么新鲜事,但话说回来,市场会选择何时做出反应,而不是拿着键盘的人。</blockquote></p><p> If you listen to the thrum of the Street, though, you get the sense that the market has been due for a correction. There’s some truth to that. The S&P 500 has been more than 8% above its 200-day moving average for 198 days, the longest in 40 years and among the five longest stretches in history. These streaks are usually followed by a couple of months of choppy trading, with a median gain of just 0.3% over the following two months. “By the time it reached the current length, other super-strong trends saw buyers take a break,” writes Sundial Capital Research’s Jason Goepfert.</p><p><blockquote>不过,如果你听听街上的喧闹声,你会觉得市场已经到了调整的时候了。这有一定的道理。标普500已经有198天比200日移动平均线高出8%以上,这是40年来最长的一次,也是历史上最长的五次之一。这些连涨之后通常会出现几个月的波动交易,接下来两个月的中值涨幅仅为0.3%。Sundial Capital Research的Jason Goepfert写道:“当它达到目前的长度时,其他超级强劲的趋势让买家休息一下。”</blockquote></p><p> Of course, it might just be August, says DataTrek’s Nicholas Colas. He notes that the S&P 500 typically has one 1% up or down move every week since 1957, but has had just three during the first seven weeks of the third quarter. August, because of its low volume and history of higher volatility would be a good time to catch up.</p><p><blockquote>DataTrek的尼古拉斯·科拉斯(Nicholas Colas)表示,当然,可能只是八月。他指出,自1957年以来,标普500通常每周都会上涨或下跌1%,但第三季度前七周仅上涨或下跌3次。八月,由于其交易量较低且波动性较高的历史,将是追赶的好时机。</blockquote></p><p> That’s especially true with stocks starting to move together again. “[As] much as we like U.S. equities, we have to respect both the tape (suddenly higher correlations) and seasonality (late August volatility),” Colas writes. “Both tell us to be cautious over the next 2-3 weeks.”</p><p><blockquote>当股市再次开始同步波动时尤其如此。科拉斯写道:“尽管我们非常喜欢美国股市,但我们必须尊重磁带(相关性突然上升)和季节性(八月下旬的波动性)。”“两者都告诉我们在未来2-3周内要保持谨慎。”</blockquote></p><p> So buckle up. Whatever the reason, it’s chop time for U.S. stock markets.</p><p><blockquote>所以系好安全带。不管是什么原因,现在是美国股市下跌的时候了。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://www.barrons.com/articles/why-stock-market-dropping-again-today-51629372284?mod=hp_LEAD_3_B_1&tesla=y\">Barron's</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://www.barrons.com/articles/why-stock-market-dropping-again-today-51629372284?mod=hp_LEAD_3_B_1&tesla=y","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169769842","content_text":"The S&P 500 is on pace for its worst three-day drop since July. Is the sky starting to fall?\nIt sure does look ugly out there. S&P 500 futures have declined 0.6% Thursday morning, indicating an opening loss of around 28 points, or 0.6%, for the index. The Dow Jones Industrial Average (DJIA), meanwhile, could be headed for a 237 point, or 0.7%, decline, per futures markets.\nIf the losses hold, it would be the S&P 500’s third consecutive drop, the index’s longest losing streak since the three-day losing streak that ended on July 19. At this pace, the index would shed around 2.4% over a three-day period, also the worst since that July tumble.\nIf you want reasons for the decline, well, there are plenty. Taper fears are at the top of the list, despite the fact that the Fed has been about as transparent about the fact that it will end its bond-buying program soon as it’s possible to be. (Can a big article in The Wall Street Journal with the headline “Fed Officials Weigh Ending Asset Purchases by Mid-2022” be any more obvious?)\nBut history shows that markets react to changes in monetary policy—even when they know the change is coming, says Bleakley Advisory Group’s Peter Boockvar. “[We] have to be reminded of how stocks responded to EVERY SINGLE change in Fed policy towards tightening since 2010,” he writes. “Outside of the August 2015 selloff related to the Chinese yuan modest devaluation and the Covid induced crash, every notable correction in stocks surrounded a change Fed policy toward tightening.”\nCovid concerns continue to rise, whether its cases forcing shutdowns in New Zealand or reports that the vaccines aren’t as effective against the Delta variant as originally thought. Again, none of this is terribly new, but then again, the market chooses when it wants to react, not folks with a keyboard.\nIf you listen to the thrum of the Street, though, you get the sense that the market has been due for a correction. There’s some truth to that. The S&P 500 has been more than 8% above its 200-day moving average for 198 days, the longest in 40 years and among the five longest stretches in history. These streaks are usually followed by a couple of months of choppy trading, with a median gain of just 0.3% over the following two months. “By the time it reached the current length, other super-strong trends saw buyers take a break,” writes Sundial Capital Research’s Jason Goepfert.\nOf course, it might just be August, says DataTrek’s Nicholas Colas. He notes that the S&P 500 typically has one 1% up or down move every week since 1957, but has had just three during the first seven weeks of the third quarter. August, because of its low volume and history of higher volatility would be a good time to catch up.\nThat’s especially true with stocks starting to move together again. “[As] much as we like U.S. equities, we have to respect both the tape (suddenly higher correlations) and seasonality (late August volatility),” Colas writes. “Both tell us to be cautious over the next 2-3 weeks.”\nSo buckle up. Whatever the reason, it’s chop time for U.S. stock markets.","news_type":1,"symbols_score_info":{".SPX":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":1514,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":838620677,"gmtCreate":1629394927699,"gmtModify":1633685162761,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570801892131113","idStr":"3570801892131113"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/838620677","repostId":"1102855434","repostType":4,"isVote":1,"tweetType":1,"viewCount":1475,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":831970595,"gmtCreate":1629283833017,"gmtModify":1633685998932,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570801892131113","idStr":"3570801892131113"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/831970595","repostId":"1129654171","repostType":4,"repost":{"id":"1129654171","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1629276411,"share":"https://www.laohu8.com/m/news/1129654171?lang=zh_CN&edition=full","pubTime":"2021-08-18 16:46","market":"hk","language":"en","title":"Tencent second-quarter profit rises 29%<blockquote>腾讯控股第二季度利润增长29%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1129654171","media":"Tiger Newspress","summary":"(Aug 18) Chinese gaming and social media giant Tencent Holdings(0700.HK)posted a 29% rise in second-","content":"<p>(Aug 18) Chinese gaming and social media giant Tencent Holdings(0700.HK)posted a 29% rise in second-quarter profit, a slower pace of growth after the coronavirus pandemic led to a boom in online gaming last year.</p><p><blockquote>(8月18日)中国游戏和社交媒体巨头腾讯控股控股(0700.HK)公布第二季度利润增长29%,在去年冠状病毒疫情导致在线游戏繁荣后,增长速度放缓。</blockquote></p><p> Net profit for the three months through June came in at 42.6 billion yuan, above an average Refinitiv estimate drawn from 13 analysts of 34.4 billion yuan.</p><p><blockquote>截至6月份的三个月净利润为426亿元人民币,高于路孚特13位分析师平均预期的344亿元人民币。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/0c6a35977c62913bdc8dae5672c11cda\" tg-width=\"1230\" tg-height=\"606\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tencent second-quarter profit rises 29%<blockquote>腾讯控股第二季度利润增长29%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTencent second-quarter profit rises 29%<blockquote>腾讯控股第二季度利润增长29%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-08-18 16:46</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(Aug 18) Chinese gaming and social media giant Tencent Holdings(0700.HK)posted a 29% rise in second-quarter profit, a slower pace of growth after the coronavirus pandemic led to a boom in online gaming last year.</p><p><blockquote>(8月18日)中国游戏和社交媒体巨头腾讯控股控股(0700.HK)公布第二季度利润增长29%,在去年冠状病毒疫情导致在线游戏繁荣后,增长速度放缓。</blockquote></p><p> Net profit for the three months through June came in at 42.6 billion yuan, above an average Refinitiv estimate drawn from 13 analysts of 34.4 billion yuan.</p><p><blockquote>截至6月份的三个月净利润为426亿元人民币,高于路孚特13位分析师平均预期的344亿元人民币。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/0c6a35977c62913bdc8dae5672c11cda\" tg-width=\"1230\" tg-height=\"606\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"00700":"腾讯控股","TCEHY":"腾讯控股ADR"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129654171","content_text":"(Aug 18) Chinese gaming and social media giant Tencent Holdings(0700.HK)posted a 29% rise in second-quarter profit, a slower pace of growth after the coronavirus pandemic led to a boom in online gaming last year.\nNet profit for the three months through June came in at 42.6 billion yuan, above an average Refinitiv estimate drawn from 13 analysts of 34.4 billion yuan.","news_type":1,"symbols_score_info":{"TCEHY":0.9,"00700":0.9}},"isVote":1,"tweetType":1,"viewCount":2611,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":839098224,"gmtCreate":1629104472268,"gmtModify":1633687377939,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570801892131113","idStr":"3570801892131113"},"themes":[],"htmlText":"RIP","listText":"RIP","text":"RIP","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/839098224","repostId":"1119726374","repostType":4,"isVote":1,"tweetType":1,"viewCount":2995,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":830350437,"gmtCreate":1629016220829,"gmtModify":1633687938211,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570801892131113","idStr":"3570801892131113"},"themes":[],"htmlText":"[财迷] ","listText":"[财迷] ","text":"[财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/830350437","repostId":"1138531277","repostType":4,"isVote":1,"tweetType":1,"viewCount":1802,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":897466101,"gmtCreate":1628961751903,"gmtModify":1633688289691,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570801892131113","idStr":"3570801892131113"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/897466101","repostId":"1101274827","repostType":4,"isVote":1,"tweetType":1,"viewCount":2861,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":895593862,"gmtCreate":1628754001156,"gmtModify":1633689759982,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570801892131113","idStr":"3570801892131113"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/895593862","repostId":"2158936289","repostType":4,"isVote":1,"tweetType":1,"viewCount":3118,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":892517469,"gmtCreate":1628672053051,"gmtModify":1633745227453,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570801892131113","idStr":"3570801892131113"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/892517469","repostId":"1166126919","repostType":4,"isVote":1,"tweetType":1,"viewCount":1726,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896258459,"gmtCreate":1628587246671,"gmtModify":1633745943266,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570801892131113","idStr":"3570801892131113"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/896258459","repostId":"1127196790","repostType":4,"isVote":1,"tweetType":1,"viewCount":2175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898897882,"gmtCreate":1628482780746,"gmtModify":1633746800080,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570801892131113","idStr":"3570801892131113"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/898897882","repostId":"2157492988","repostType":4,"isVote":1,"tweetType":1,"viewCount":1861,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":891121937,"gmtCreate":1628351635729,"gmtModify":1633751503672,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570801892131113","idStr":"3570801892131113"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/891121937","repostId":"1139912651","repostType":4,"isVote":1,"tweetType":1,"viewCount":636,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":893187354,"gmtCreate":1628246807678,"gmtModify":1633752279672,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570801892131113","idStr":"3570801892131113"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/893187354","repostId":"1128779869","repostType":4,"isVote":1,"tweetType":1,"viewCount":726,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890033622,"gmtCreate":1628065255566,"gmtModify":1633753919051,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570801892131113","idStr":"3570801892131113"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/890033622","repostId":"1124757232","repostType":4,"repost":{"id":"1124757232","kind":"news","pubTimestamp":1628045612,"share":"https://www.laohu8.com/m/news/1124757232?lang=zh_CN&edition=full","pubTime":"2021-08-04 10:53","market":"us","language":"en","title":"3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1124757232","media":"The Motley Fool","summary":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfi","content":"<p><b><i>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.</i></b></p><p><blockquote><b><i>这就是为什么辉瑞、Inari Medical和Novavax的股票在2021年可能更有价值。</i></b></blockquote></p><p> <b>Key Points</b></p><p><blockquote><b>要点</b></blockquote></p><p> <ul> <li>Pfizer might surprise to the upside.</li> <li>Inari Medical is growing like gangbusters.</li> <li>Novavax's vaccine might be an important booster shot as the COVID-19 virus mutates.</li> </ul> COVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?</p><p><blockquote><ul><li>辉瑞可能会带来惊喜。</li><li>伊那里医疗公司正在飞速发展。</li><li>随着COVID-19病毒的变异,Novavax的疫苗可能是一剂重要的加强针。</li></ul>2020年,新冠肺炎和国际封锁导致世界经济崩溃。许多人已经接种了疫苗,并期待正常化。但COVID正在变异,新的德尔塔变异毒株可能会给世界的重新开放带来麻烦。投资者如何保护自己?</blockquote></p><p> A panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">Inari Medical, Inc.</a></b>, and <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</p><p><blockquote>Motley Fool撰稿人小组为医疗保健股提供了三个想法,即使新冠疫情形势恶化,这些股票也将在2021年飙升。阅读更多内容,了解为什么您可能想购买<b><a href=\"https://laohu8.com/S/PFE\">辉瑞</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">伊那里医疗公司。</a></b>,和<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f3ed6a343e35e121aafbaa2b30134955\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源:盖蒂图片社。</span></p></blockquote></p><p> <h3><b>Pfizer: More room to run</b></h3> <b>George Budwell</b> <b>(Pfizer):</b> American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> -- losing steam from a sales perspective starting in 2022.</p><p><blockquote><h3><b>辉瑞:更多运行空间</b></h3><b>乔治·布德维尔</b> <b>(辉瑞):</b>在目前的新冠疫苗公司中,美国制药巨头辉瑞听起来可能不是一个性感的选择。华尔街目前的共识是制药商Comirnaty的疫苗——与<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>——从2022年开始,从销售角度来看失去动力。</blockquote></p><p> Because of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.</p><p><blockquote>然而,由于德尔塔变异毒株,Comirnaty的商业寿命可能会比最初预期的长得多。虽然高传播变种的出现对整个社会来说显然是个坏消息,但辉瑞及其股东可能会从这一不幸的发展中受益。</blockquote></p><p> There are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company announced that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.</p><p><blockquote>有两个明显的理由认为辉瑞的股价可能会因达美航空问题而走高。首先,该公司宣布,最早可能在本月提交第三次加强注射的紧急使用授权。其次,辉瑞计划本月启动德尔塔特异性版本疫苗的临床试验。</blockquote></p><p> Although the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.</p><p><blockquote>尽管美国食品药品监督管理局和疾病控制与预防中心最近都淡化了加强注射的必要性,但辉瑞已经提出了第三次注射的令人信服的理由,以应对德尔塔变异毒株的猖獗传播和Comirnaty在完全接种疫苗后6至12个月的疗效减弱。</blockquote></p><p> The big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.</p><p><blockquote>对于投资者来说,总体情况是,辉瑞2022年的收入可能比2021年增长9.7%——也就是说,如果加强注射确实获得批准,并且该公司还成功开发了delta特异性疫苗。相比之下,华尔街目前预计该制药商明年的营收将比2021年下降14.8%。</blockquote></p><p> Where is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a dividend-paying big pharma stock.</p><p><blockquote>辉瑞的股票可能走向何方?从保守的角度来看,如果疫苗方面的所有部分都到位,股价应该会达到50美元。这比该制药商的股价目前上涨了大约17%,甚至还没有考虑到该公司当前水平上颇具吸引力的3.64%股息收益率。简而言之,如果这种情况实现,辉瑞的股票交易价格将仅为2022年销售额的约3.5倍,对于派息的大型制药股来说,这是一个相当适中的估值。</blockquote></p><p> <h3><b>Inari Medical: Skyrocketing Sales</b></h3> <b>Patrick Bafuma</b> <b>(Inari Medical):</b> If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to <i>The New York Times</i> -- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.</p><p><blockquote><h3><b>伊那里医疗:销售额暴涨</b></h3><b>帕特里克·巴富马</b> <b>(伊那里医疗):</b>如果您正在寻找一只在大流行的顺风消退后具有持久力的股票,请关注伊那里医疗。数据显示,2021年7月27日新增108,000例新冠病例,为2021年2月5日以来最多<i>纽约时报</i>——这个数字是7月初7天平均水平的八倍多。更糟糕的是,COVID不仅会导致呼吸困难,还会使患者患致残和可能危及生命的血栓的风险增加两倍以上。我们仍然不确定当患者无症状或轻度COVID感染时,接种疫苗是否能完全降低血栓的风险。</blockquote></p><p></p><p> This seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021, up 130% from the same quarter last year and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according to<i>The Times</i>, Inari is likely to see an uptick in eligible cases.</p><p><blockquote>对于一家商业阶段的医疗技术公司来说,这似乎是一个很好的设置,该公司开发了微创产品,旨在消除大血凝块,而不需要强大的血栓破坏药物。通过使用ClotTriever和FlowTriever设备,伊那里迄今已治疗了25,000多名患者。2021年第一季度,临床医生使用该公司的设备进行了约5,500次手术,比去年同季度增长130%,比2020年第四季度增长约20%。根据数据,截至7月27日,美国约有12%的新冠肺炎患者出现血栓,约有35,000人因新冠肺炎住院(并且还在增加)<i>纽约时报</i>,伊那里可能会看到符合条件的病例增加。</blockquote></p><p> Not to mention the company's results thus far for blood clots in the lung are spectacular:</p><p><blockquote>更不用说该公司迄今为止在肺部血栓方面的结果非常惊人:</blockquote></p><p> <ul> <li>With the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.</li> <li>There's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.</li> <li>Major adverse events within 48 hours occur at only a 1.3% rate.</li> <li>No ICU stays are required after the procedure.</li> </ul> Add it all up, and Inari's retrieval device seems like an obvious choice.</p><p><blockquote><ul><li>由于肺部中高风险血栓的历史30天死亡率为9.7%,伊那里0.4%的30天死亡率令人印象深刻。</li><li>30天再入院率降低了6.7%,而常规护理为24.4%。</li><li>48小时内的主要不良事件发生率仅为1.3%。</li><li>手术后不需要住ICU。</li></ul>所有这些加起来,伊那里的检索设备似乎是一个显而易见的选择。</blockquote></p><p> The company grew first-quarter revenue at 113% year over year, and 18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.</p><p><blockquote>该公司第一季度收入同比增长113%,环比增长18%,2021年第一季度毛利率为91.9%。因此,伊那里的市销率为18,使其成为一只正在出售的成长型股票。</blockquote></p><p> Inari has less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.</p><p><blockquote>Inari在价值38亿美元的美国市场的渗透率不到5%,今年早些时候在欧洲推出的市场也有很大的增长空间。这意味着这家市值45亿美元的公司有很多机会。虽然COVID影响了许多选择性和半选择性程序,但它显然没有减缓伊那里,甚至可能加速其吸收。</blockquote></p><p> <h3><b>Novavax: How high can it go?</b></h3> <b>Taylor Carmichael</b> <b>(Novavax):</b> The vaccine biotech Novavax had an amazing 2020, with its share price running up 2,700% on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.</p><p><blockquote><h3><b>Novavax:能涨到多高?</b></h3><b>泰勒·卡迈克尔</b> <b>(诺瓦瓦克斯):</b>疫苗生物技术公司Novavax在2020年表现出色,由于对其COVID疫苗的乐观情绪,其股价上涨了2700%。虽然该公司尚未申请紧急使用授权,但预计将在本季度申请。2021年迄今为止,该股已上涨60%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e7829d99a76c48579ba01c6e55fe14f\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>NVAX DATA BY YCHARTS.</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCHARTS提供的NVAX数据。</span></p></blockquote></p><p> Positive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.</p><p><blockquote>COVID-19疫苗第三阶段的积极数据导致该股在今年年初飙升,但由于该公司的疫苗上市延迟,股价已经回落。首先,制造疫苗所需的原材料短缺。现在,该公司必须证明其各种合同生产设施将保持所有地点的疫苗质量一致。</blockquote></p><p> Despite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.</p><p><blockquote>尽管存在这些延迟,但长期投资者有理由看涨。制造业正在扩大规模,预计到第三季度末,生产率将达到每月1亿剂,到12月将达到每月1.5亿剂。虽然美国的许多人已经接种了疫苗,但世界其他地方的机会相当大。Novavax已向COVAX(国际疫苗联盟)预售了11亿剂疫苗,并已签约在全球范围内供应数亿剂疫苗。</blockquote></p><p> In the U.S., the Novavax vaccine might primarily be used as a booster shot for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told <i>The New York Times</i>.</p><p><blockquote>在美国,Novavax疫苗可能主要用于已经接种疫苗的人的加强注射。FDA代理首席科学家露丝安娜·博里奥(Luciana Borio)博士表示:“它们可能确实适合加强剂。”从2015年到2017年,告诉<i>纽约时报</i>.</blockquote></p><p> Down the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.</p><p><blockquote>未来,Novavax计划将其新冠疫苗与流感疫苗结合起来,形成一种一次性疗法。虽然COVID的变异速度不如流感,但我们在过去一年中已经看到了几种变异毒株。在未来的几年里,我们很可能需要不止一次接种疫苗。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Motley Fool</strong><span class=\"h-time small\">2021-08-04 10:53</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b><i>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.</i></b></p><p><blockquote><b><i>这就是为什么辉瑞、Inari Medical和Novavax的股票在2021年可能更有价值。</i></b></blockquote></p><p> <b>Key Points</b></p><p><blockquote><b>要点</b></blockquote></p><p> <ul> <li>Pfizer might surprise to the upside.</li> <li>Inari Medical is growing like gangbusters.</li> <li>Novavax's vaccine might be an important booster shot as the COVID-19 virus mutates.</li> </ul> COVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?</p><p><blockquote><ul><li>辉瑞可能会带来惊喜。</li><li>伊那里医疗公司正在飞速发展。</li><li>随着COVID-19病毒的变异,Novavax的疫苗可能是一剂重要的加强针。</li></ul>2020年,新冠肺炎和国际封锁导致世界经济崩溃。许多人已经接种了疫苗,并期待正常化。但COVID正在变异,新的德尔塔变异毒株可能会给世界的重新开放带来麻烦。投资者如何保护自己?</blockquote></p><p> A panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">Inari Medical, Inc.</a></b>, and <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</p><p><blockquote>Motley Fool撰稿人小组为医疗保健股提供了三个想法,即使新冠疫情形势恶化,这些股票也将在2021年飙升。阅读更多内容,了解为什么您可能想购买<b><a href=\"https://laohu8.com/S/PFE\">辉瑞</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">伊那里医疗公司。</a></b>,和<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f3ed6a343e35e121aafbaa2b30134955\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源:盖蒂图片社。</span></p></blockquote></p><p> <h3><b>Pfizer: More room to run</b></h3> <b>George Budwell</b> <b>(Pfizer):</b> American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> -- losing steam from a sales perspective starting in 2022.</p><p><blockquote><h3><b>辉瑞:更多运行空间</b></h3><b>乔治·布德维尔</b> <b>(辉瑞):</b>在目前的新冠疫苗公司中,美国制药巨头辉瑞听起来可能不是一个性感的选择。华尔街目前的共识是制药商Comirnaty的疫苗——与<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>——从2022年开始,从销售角度来看失去动力。</blockquote></p><p> Because of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.</p><p><blockquote>然而,由于德尔塔变异毒株,Comirnaty的商业寿命可能会比最初预期的长得多。虽然高传播变种的出现对整个社会来说显然是个坏消息,但辉瑞及其股东可能会从这一不幸的发展中受益。</blockquote></p><p> There are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company announced that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.</p><p><blockquote>有两个明显的理由认为辉瑞的股价可能会因达美航空问题而走高。首先,该公司宣布,最早可能在本月提交第三次加强注射的紧急使用授权。其次,辉瑞计划本月启动德尔塔特异性版本疫苗的临床试验。</blockquote></p><p> Although the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.</p><p><blockquote>尽管美国食品药品监督管理局和疾病控制与预防中心最近都淡化了加强注射的必要性,但辉瑞已经提出了第三次注射的令人信服的理由,以应对德尔塔变异毒株的猖獗传播和Comirnaty在完全接种疫苗后6至12个月的疗效减弱。</blockquote></p><p> The big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.</p><p><blockquote>对于投资者来说,总体情况是,辉瑞2022年的收入可能比2021年增长9.7%——也就是说,如果加强注射确实获得批准,并且该公司还成功开发了delta特异性疫苗。相比之下,华尔街目前预计该制药商明年的营收将比2021年下降14.8%。</blockquote></p><p> Where is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a dividend-paying big pharma stock.</p><p><blockquote>辉瑞的股票可能走向何方?从保守的角度来看,如果疫苗方面的所有部分都到位,股价应该会达到50美元。这比该制药商的股价目前上涨了大约17%,甚至还没有考虑到该公司当前水平上颇具吸引力的3.64%股息收益率。简而言之,如果这种情况实现,辉瑞的股票交易价格将仅为2022年销售额的约3.5倍,对于派息的大型制药股来说,这是一个相当适中的估值。</blockquote></p><p> <h3><b>Inari Medical: Skyrocketing Sales</b></h3> <b>Patrick Bafuma</b> <b>(Inari Medical):</b> If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to <i>The New York Times</i> -- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.</p><p><blockquote><h3><b>伊那里医疗:销售额暴涨</b></h3><b>帕特里克·巴富马</b> <b>(伊那里医疗):</b>如果您正在寻找一只在大流行的顺风消退后具有持久力的股票,请关注伊那里医疗。数据显示,2021年7月27日新增108,000例新冠病例,为2021年2月5日以来最多<i>纽约时报</i>——这个数字是7月初7天平均水平的八倍多。更糟糕的是,COVID不仅会导致呼吸困难,还会使患者患致残和可能危及生命的血栓的风险增加两倍以上。我们仍然不确定当患者无症状或轻度COVID感染时,接种疫苗是否能完全降低血栓的风险。</blockquote></p><p></p><p> This seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021, up 130% from the same quarter last year and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according to<i>The Times</i>, Inari is likely to see an uptick in eligible cases.</p><p><blockquote>对于一家商业阶段的医疗技术公司来说,这似乎是一个很好的设置,该公司开发了微创产品,旨在消除大血凝块,而不需要强大的血栓破坏药物。通过使用ClotTriever和FlowTriever设备,伊那里迄今已治疗了25,000多名患者。2021年第一季度,临床医生使用该公司的设备进行了约5,500次手术,比去年同季度增长130%,比2020年第四季度增长约20%。根据数据,截至7月27日,美国约有12%的新冠肺炎患者出现血栓,约有35,000人因新冠肺炎住院(并且还在增加)<i>纽约时报</i>,伊那里可能会看到符合条件的病例增加。</blockquote></p><p> Not to mention the company's results thus far for blood clots in the lung are spectacular:</p><p><blockquote>更不用说该公司迄今为止在肺部血栓方面的结果非常惊人:</blockquote></p><p> <ul> <li>With the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.</li> <li>There's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.</li> <li>Major adverse events within 48 hours occur at only a 1.3% rate.</li> <li>No ICU stays are required after the procedure.</li> </ul> Add it all up, and Inari's retrieval device seems like an obvious choice.</p><p><blockquote><ul><li>由于肺部中高风险血栓的历史30天死亡率为9.7%,伊那里0.4%的30天死亡率令人印象深刻。</li><li>30天再入院率降低了6.7%,而常规护理为24.4%。</li><li>48小时内的主要不良事件发生率仅为1.3%。</li><li>手术后不需要住ICU。</li></ul>所有这些加起来,伊那里的检索设备似乎是一个显而易见的选择。</blockquote></p><p> The company grew first-quarter revenue at 113% year over year, and 18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.</p><p><blockquote>该公司第一季度收入同比增长113%,环比增长18%,2021年第一季度毛利率为91.9%。因此,伊那里的市销率为18,使其成为一只正在出售的成长型股票。</blockquote></p><p> Inari has less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.</p><p><blockquote>Inari在价值38亿美元的美国市场的渗透率不到5%,今年早些时候在欧洲推出的市场也有很大的增长空间。这意味着这家市值45亿美元的公司有很多机会。虽然COVID影响了许多选择性和半选择性程序,但它显然没有减缓伊那里,甚至可能加速其吸收。</blockquote></p><p> <h3><b>Novavax: How high can it go?</b></h3> <b>Taylor Carmichael</b> <b>(Novavax):</b> The vaccine biotech Novavax had an amazing 2020, with its share price running up 2,700% on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.</p><p><blockquote><h3><b>Novavax:能涨到多高?</b></h3><b>泰勒·卡迈克尔</b> <b>(诺瓦瓦克斯):</b>疫苗生物技术公司Novavax在2020年表现出色,由于对其COVID疫苗的乐观情绪,其股价上涨了2700%。虽然该公司尚未申请紧急使用授权,但预计将在本季度申请。2021年迄今为止,该股已上涨60%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e7829d99a76c48579ba01c6e55fe14f\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>NVAX DATA BY YCHARTS.</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCHARTS提供的NVAX数据。</span></p></blockquote></p><p> Positive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.</p><p><blockquote>COVID-19疫苗第三阶段的积极数据导致该股在今年年初飙升,但由于该公司的疫苗上市延迟,股价已经回落。首先,制造疫苗所需的原材料短缺。现在,该公司必须证明其各种合同生产设施将保持所有地点的疫苗质量一致。</blockquote></p><p> Despite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.</p><p><blockquote>尽管存在这些延迟,但长期投资者有理由看涨。制造业正在扩大规模,预计到第三季度末,生产率将达到每月1亿剂,到12月将达到每月1.5亿剂。虽然美国的许多人已经接种了疫苗,但世界其他地方的机会相当大。Novavax已向COVAX(国际疫苗联盟)预售了11亿剂疫苗,并已签约在全球范围内供应数亿剂疫苗。</blockquote></p><p> In the U.S., the Novavax vaccine might primarily be used as a booster shot for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told <i>The New York Times</i>.</p><p><blockquote>在美国,Novavax疫苗可能主要用于已经接种疫苗的人的加强注射。FDA代理首席科学家露丝安娜·博里奥(Luciana Borio)博士表示:“它们可能确实适合加强剂。”从2015年到2017年,告诉<i>纽约时报</i>.</blockquote></p><p> Down the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.</p><p><blockquote>未来,Novavax计划将其新冠疫苗与流感疫苗结合起来,形成一种一次性疗法。虽然COVID的变异速度不如流感,但我们在过去一年中已经看到了几种变异毒株。在未来的几年里,我们很可能需要不止一次接种疫苗。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/\">The Motley Fool</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NARI":"Inari Medical, Inc.","NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124757232","content_text":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfizer might surprise to the upside.\nInari Medical is growing like gangbusters.\nNovavax's vaccine might be an important booster shot as the COVID-19 virus mutates.\n\nCOVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?\nA panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of Pfizer, Inari Medical, Inc., and Novavax.\nIMAGE SOURCE: GETTY IMAGES.\nPfizer: More room to run\nGeorge Budwell (Pfizer): American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with BioNTech SE -- losing steam from a sales perspective starting in 2022.\nBecause of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.\nThere are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company announced that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.\nAlthough the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.\nThe big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.\nWhere is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a dividend-paying big pharma stock.\nInari Medical: Skyrocketing Sales\nPatrick Bafuma (Inari Medical): If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to The New York Times -- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.\nThis seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021, up 130% from the same quarter last year and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according toThe Times, Inari is likely to see an uptick in eligible cases.\nNot to mention the company's results thus far for blood clots in the lung are spectacular:\n\nWith the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.\nThere's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.\nMajor adverse events within 48 hours occur at only a 1.3% rate.\nNo ICU stays are required after the procedure.\n\nAdd it all up, and Inari's retrieval device seems like an obvious choice.\nThe company grew first-quarter revenue at 113% year over year, and 18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.\nInari has less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.\nNovavax: How high can it go?\nTaylor Carmichael (Novavax): The vaccine biotech Novavax had an amazing 2020, with its share price running up 2,700% on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.\nNVAX DATA BY YCHARTS.\nPositive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.\nDespite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.\nIn the U.S., the Novavax vaccine might primarily be used as a booster shot for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told The New York Times.\nDown the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.","news_type":1,"symbols_score_info":{"NARI":0.9,"PFE":0.9,"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":469,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":805760002,"gmtCreate":1627907427306,"gmtModify":1633755423784,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570801892131113","idStr":"3570801892131113"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/805760002","repostId":"1191057621","repostType":4,"isVote":1,"tweetType":1,"viewCount":792,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":809563950,"gmtCreate":1627379776070,"gmtModify":1633765564847,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570801892131113","idStr":"3570801892131113"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/809563950","repostId":"2154899497","repostType":4,"repost":{"id":"2154899497","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1627377481,"share":"https://www.laohu8.com/m/news/2154899497?lang=zh_CN&edition=full","pubTime":"2021-07-27 17:18","market":"us","language":"en","title":"7 Stocks To Watch For July 27, 2021<blockquote>2021年7月27日值得关注的7只股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2154899497","media":"Benzinga","summary":"Some of the stocks that may grab investor focus today are:\n\tWall Street expects General Electric Company (NYSE: GE) to report quarterly earnings at $0.04 per share on revenue of $18.13 billion before the opening bell. GE shares rose 0.8% to $13.02 in after-hours trading.\n","content":"<p>Some of the stocks that may grab investor focus today are:</p><p><blockquote>今天可能引起投资者关注的一些股票包括:</blockquote></p><p> <ul> <li>Wall Street expects <b>General Electric Company</b> (NYSE:GE) to report quarterly earnings at $0.04 per share on revenue of $18.13 billion before the opening bell. GE shares rose 0.8% to $13.02 in after-hours trading.</li> <li>Analysts are expecting <b>Apple Inc</b> (NASDAQ:AAPL) to have earned $1.00 per share on revenue of $72.93 billion for the latest quarter. The company will release earnings after the markets close. Apple shares gained 0.2% to $149.26 in after-hours trading.</li> <li><b>Tesla Inc</b> (NASDAQ:TSLA) reported stronger-than-expected results for its second quarter on Monday. Total vehicle production totaled 206,421, up 151% year over year. Deliveries in the second quarter were up 121% year-over-year to 201,304. Tesla shares gained 1% to $664.16 in the after-hours trading session.</li> </ul> <ul> <li>After the closing bell, <b>Alphabet Inc</b> (NASDAQ:GOOGL) is projected to post quarterly earnings at $19.21 per share on revenue of $56.02 billion. Alphabet shares gained 0.5% to $2,694.00 in after-hours trading.</li> <li>Analysts expect <b><a href=\"https://laohu8.com/S/MMM\">3M</a> Co</b> (NYSE:MMM) to report quarterly earnings at $2.26 per share on revenue of $8.55 billion before the opening bell. 3M shares slipped 0.1% to $201.50 in after-hours trading.</li> <li><b>F5 Networks</b> (NASDAQ:FFIV) reported upbeat results for its third quarter. The company also said it sees Q4 adjusted earnings of $2.68 to $2.80 per share on sales of $660 million to $680 million. F5 Networks shares surged 6.1% to $204.27 in the after-hours trading session.</li> <li>Analysts expect <b>Microsoft Corporation</b> (NASDAQ:MSFT) to post quarterly earnings at $1.90 per share on revenue of $44.10 billion after the closing bell. Microsoft shares rose 0.2% to $289.62 in after-hours trading.</li> </ul></p><p><blockquote><ul><li>华尔街预计<b>通用电气公司</b>(纽约证券交易所股票代码:GE)将在开盘前公布季度收益为每股0.04美元,营收为181.3亿美元。GE股价在盘后交易中上涨0.8%,至13.02美元。</li><li>分析师预计<b>苹果公司</b>(纳斯达克股票代码:AAPL)最近一个季度的营收为729.3亿美元,每股收益为1.00美元。该公司将在收盘后发布财报。苹果股价在盘后交易中上涨0.2%,至149.26美元。</li><li><b>特斯拉公司</b>(纳斯达克:TSLA)周一公布了强于预期的第二季度业绩。汽车总产量206,421辆,同比增长151%。第二季度交付量同比增长121%至201,304辆。特斯拉股价在盘后交易时段上涨1%,至664.16美元。</li></ul><ul><li>收盘后,<b>Alphabet公司</b>(纳斯达克:GOOGL)预计季度收益为每股19.21美元,营收为560.2亿美元。Alphabet股价在盘后交易中上涨0.5%,至2,694.00美元。</li><li>分析师预计<b><a href=\"https://laohu8.com/S/MMM\">3M</a>Co</b>(纽约证券交易所股票代码:3M)将在开盘前公布季度收益为每股2.26美元,营收为85.5亿美元。3M股价在盘后交易中下跌0.1%,至201.50美元。</li><li><b>F5网络</b>(纳斯达克:FFIV)公布了乐观的第三季度业绩。该公司还表示,预计第四季度调整后每股收益为2.68美元至2.80美元,销售额为6.6亿美元至6.8亿美元。F5 Networks股价在盘后交易时段飙升6.1%至204.27美元。</li><li>分析师预计<b>微软公司</b>(纳斯达克股票代码:MSFT)收盘后公布季度收益为每股1.90美元,营收为441亿美元。微软股价在盘后交易中上涨0.2%,至289.62美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 Stocks To Watch For July 27, 2021<blockquote>2021年7月27日值得关注的7只股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 Stocks To Watch For July 27, 2021<blockquote>2021年7月27日值得关注的7只股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-07-27 17:18</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>Some of the stocks that may grab investor focus today are:</p><p><blockquote>今天可能引起投资者关注的一些股票包括:</blockquote></p><p> <ul> <li>Wall Street expects <b>General Electric Company</b> (NYSE:GE) to report quarterly earnings at $0.04 per share on revenue of $18.13 billion before the opening bell. GE shares rose 0.8% to $13.02 in after-hours trading.</li> <li>Analysts are expecting <b>Apple Inc</b> (NASDAQ:AAPL) to have earned $1.00 per share on revenue of $72.93 billion for the latest quarter. The company will release earnings after the markets close. Apple shares gained 0.2% to $149.26 in after-hours trading.</li> <li><b>Tesla Inc</b> (NASDAQ:TSLA) reported stronger-than-expected results for its second quarter on Monday. Total vehicle production totaled 206,421, up 151% year over year. Deliveries in the second quarter were up 121% year-over-year to 201,304. Tesla shares gained 1% to $664.16 in the after-hours trading session.</li> </ul> <ul> <li>After the closing bell, <b>Alphabet Inc</b> (NASDAQ:GOOGL) is projected to post quarterly earnings at $19.21 per share on revenue of $56.02 billion. Alphabet shares gained 0.5% to $2,694.00 in after-hours trading.</li> <li>Analysts expect <b><a href=\"https://laohu8.com/S/MMM\">3M</a> Co</b> (NYSE:MMM) to report quarterly earnings at $2.26 per share on revenue of $8.55 billion before the opening bell. 3M shares slipped 0.1% to $201.50 in after-hours trading.</li> <li><b>F5 Networks</b> (NASDAQ:FFIV) reported upbeat results for its third quarter. The company also said it sees Q4 adjusted earnings of $2.68 to $2.80 per share on sales of $660 million to $680 million. F5 Networks shares surged 6.1% to $204.27 in the after-hours trading session.</li> <li>Analysts expect <b>Microsoft Corporation</b> (NASDAQ:MSFT) to post quarterly earnings at $1.90 per share on revenue of $44.10 billion after the closing bell. Microsoft shares rose 0.2% to $289.62 in after-hours trading.</li> </ul></p><p><blockquote><ul><li>华尔街预计<b>通用电气公司</b>(纽约证券交易所股票代码:GE)将在开盘前公布季度收益为每股0.04美元,营收为181.3亿美元。GE股价在盘后交易中上涨0.8%,至13.02美元。</li><li>分析师预计<b>苹果公司</b>(纳斯达克股票代码:AAPL)最近一个季度的营收为729.3亿美元,每股收益为1.00美元。该公司将在收盘后发布财报。苹果股价在盘后交易中上涨0.2%,至149.26美元。</li><li><b>特斯拉公司</b>(纳斯达克:TSLA)周一公布了强于预期的第二季度业绩。汽车总产量206,421辆,同比增长151%。第二季度交付量同比增长121%至201,304辆。特斯拉股价在盘后交易时段上涨1%,至664.16美元。</li></ul><ul><li>收盘后,<b>Alphabet公司</b>(纳斯达克:GOOGL)预计季度收益为每股19.21美元,营收为560.2亿美元。Alphabet股价在盘后交易中上涨0.5%,至2,694.00美元。</li><li>分析师预计<b><a href=\"https://laohu8.com/S/MMM\">3M</a>Co</b>(纽约证券交易所股票代码:3M)将在开盘前公布季度收益为每股2.26美元,营收为85.5亿美元。3M股价在盘后交易中下跌0.1%,至201.50美元。</li><li><b>F5网络</b>(纳斯达克:FFIV)公布了乐观的第三季度业绩。该公司还表示,预计第四季度调整后每股收益为2.68美元至2.80美元,销售额为6.6亿美元至6.8亿美元。F5 Networks股价在盘后交易时段飙升6.1%至204.27美元。</li><li>分析师预计<b>微软公司</b>(纳斯达克股票代码:MSFT)收盘后公布季度收益为每股1.90美元,营收为441亿美元。微软股价在盘后交易中上涨0.2%,至289.62美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GE":"GE航空航天","FFIV":"F5 Inc","09086":"华夏纳指-U","03086":"华夏纳指","QNETCN":"纳斯达克中美互联网老虎指数","MMM":"3M","TSLA":"特斯拉","GOOG":"谷歌"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154899497","content_text":"Some of the stocks that may grab investor focus today are:\n\nWall Street expects General Electric Company (NYSE:GE) to report quarterly earnings at $0.04 per share on revenue of $18.13 billion before the opening bell. GE shares rose 0.8% to $13.02 in after-hours trading.\nAnalysts are expecting Apple Inc (NASDAQ:AAPL) to have earned $1.00 per share on revenue of $72.93 billion for the latest quarter. The company will release earnings after the markets close. Apple shares gained 0.2% to $149.26 in after-hours trading.\nTesla Inc (NASDAQ:TSLA) reported stronger-than-expected results for its second quarter on Monday. Total vehicle production totaled 206,421, up 151% year over year. Deliveries in the second quarter were up 121% year-over-year to 201,304. Tesla shares gained 1% to $664.16 in the after-hours trading session.\n\n\nAfter the closing bell, Alphabet Inc (NASDAQ:GOOGL) is projected to post quarterly earnings at $19.21 per share on revenue of $56.02 billion. Alphabet shares gained 0.5% to $2,694.00 in after-hours trading.\nAnalysts expect 3M Co (NYSE:MMM) to report quarterly earnings at $2.26 per share on revenue of $8.55 billion before the opening bell. 3M shares slipped 0.1% to $201.50 in after-hours trading.\nF5 Networks (NASDAQ:FFIV) reported upbeat results for its third quarter. The company also said it sees Q4 adjusted earnings of $2.68 to $2.80 per share on sales of $660 million to $680 million. F5 Networks shares surged 6.1% to $204.27 in the after-hours trading session.\nAnalysts expect Microsoft Corporation (NASDAQ:MSFT) to post quarterly earnings at $1.90 per share on revenue of $44.10 billion after the closing bell. Microsoft shares rose 0.2% to $289.62 in after-hours trading.","news_type":1,"symbols_score_info":{"03086":0.9,"GE":0.9,"QNETCN":0.9,"MMM":0.9,"GOOG":0.9,"FFIV":0.9,"09086":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":687,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":177659248,"gmtCreate":1627213952984,"gmtModify":1633767124261,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570801892131113","idStr":"3570801892131113"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/177659248","repostId":"1115106146","repostType":4,"isVote":1,"tweetType":1,"viewCount":487,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":174142696,"gmtCreate":1627088043515,"gmtModify":1633768152330,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570801892131113","idStr":"3570801892131113"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/174142696","repostId":"2153983997","repostType":4,"isVote":1,"tweetType":1,"viewCount":329,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":175238351,"gmtCreate":1627033056973,"gmtModify":1633768610576,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570801892131113","idStr":"3570801892131113"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/175238351","repostId":"1116494249","repostType":4,"isVote":1,"tweetType":1,"viewCount":511,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172669561,"gmtCreate":1626959310253,"gmtModify":1633769388110,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570801892131113","idStr":"3570801892131113"},"themes":[],"htmlText":"No....","listText":"No....","text":"No....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/172669561","repostId":"1136039581","repostType":4,"repost":{"id":"1136039581","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1626957159,"share":"https://www.laohu8.com/m/news/1136039581?lang=zh_CN&edition=full","pubTime":"2021-07-22 20:32","market":"us","language":"en","title":"U.S. weekly jobless claims total 419,000 vs. 350,000 estimate<blockquote>美国每周初请失业金人数总计41.9万人,预估为35万人</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1136039581","media":"Tiger Newspress","summary":"(July 22) U.S. initial jobless claims jump 51,000 to 419,000 in mid-July, vs. 350,000 estimate.\nTota","content":"<p>(July 22) U.S. initial jobless claims jump 51,000 to 419,000 in mid-July, vs. 350,000 estimate.</p><p><blockquote>(7月22日)美国。7月中旬首次申请失业救济人数增加51,000人,至419,000人,而预期为350,000人。</blockquote></p><p> <b>Total Number Of Americans On The Dole Plunges By 1.2 Million As States Cut Off Emergency Aid</b></p><p><blockquote><b>由于各州切断紧急援助,领取失业救济金的美国人总数锐减120万</b></blockquote></p><p> This was not supposed to happen.</p><p><blockquote>这是不应该发生的。</blockquote></p><p> Initial jobless claims jumped significantly last week as<b>419,000 Americans filed for jobless benefits for the first time</b>(well above the prior week's 368k and expectations of a 350k print)...</p><p><blockquote>上周首次申请失业救济人数大幅上升<b>41.9万美国人首次申请失业救济</b>(远高于前一周的36.8万份和35万份的预期)...</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d8eda8482fbe99bba871d16bc5379532\" tg-width=\"980\" tg-height=\"584\" width=\"100%\" height=\"auto\"><i>Source: Bloomberg</i></p><p><blockquote><i>资料来源:彭博社</i></blockquote></p><p> Michigan and Texas saw the biggest jump in claims while New York and Oklahoma saw the best improvement...</p><p><blockquote>密歇根州和德克萨斯州的申请人数增幅最大,而纽约州和俄克拉荷马州的增幅最大...</blockquote></p><p> <img src=\"https://static.tigerbbs.com/fcb4d834111a6ca8db1254f129a11ecc\" tg-width=\"1207\" tg-height=\"1276\" width=\"100%\" height=\"auto\">'Traditional'<i>c</i>ontinuing claims were basically unchanged over the prior week's revision.</p><p><blockquote>“传统”<i>c</i>与前一周的修订相比,持续索赔基本没有变化。</blockquote></p><p> There is some good news though,<b>the total number of claims plunged by over 1.2 million last week</b>(driven by a plunge in pandemic specific aid as states began shutting off the handouts)...</p><p><blockquote>不过也有一些好消息,<b>上周索赔总数锐减超过120万</b>(由于各州开始关闭施舍,疫情特定援助大幅下降)...</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b4b991ebbb0b2782ffdd1e3059e2fc78\" tg-width=\"711\" tg-height=\"215\" width=\"100%\" height=\"auto\">But, we note that overall, there remains over 12.5 million Americans on some form of government dole...</p><p><blockquote>但是,我们注意到,总的来说,仍有超过1250万美国人领取某种形式的政府救济金...</blockquote></p><p> <img src=\"https://static.tigerbbs.com/3fe2aeac47f3bbf3eaeb7d11fd96edd3\" tg-width=\"980\" tg-height=\"586\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> <i>Source: Bloomberg</i></p><p><blockquote><i>资料来源:彭博社</i></blockquote></p><p> For context, that compares to the less than 2 million pre-pandemic-lockdowns.</p><p><blockquote>相比之下,大流行前的封锁人数不到200万。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. weekly jobless claims total 419,000 vs. 350,000 estimate<blockquote>美国每周初请失业金人数总计41.9万人,预估为35万人</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. weekly jobless claims total 419,000 vs. 350,000 estimate<blockquote>美国每周初请失业金人数总计41.9万人,预估为35万人</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-07-22 20:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(July 22) U.S. initial jobless claims jump 51,000 to 419,000 in mid-July, vs. 350,000 estimate.</p><p><blockquote>(7月22日)美国。7月中旬首次申请失业救济人数增加51,000人,至419,000人,而预期为350,000人。</blockquote></p><p> <b>Total Number Of Americans On The Dole Plunges By 1.2 Million As States Cut Off Emergency Aid</b></p><p><blockquote><b>由于各州切断紧急援助,领取失业救济金的美国人总数锐减120万</b></blockquote></p><p> This was not supposed to happen.</p><p><blockquote>这是不应该发生的。</blockquote></p><p> Initial jobless claims jumped significantly last week as<b>419,000 Americans filed for jobless benefits for the first time</b>(well above the prior week's 368k and expectations of a 350k print)...</p><p><blockquote>上周首次申请失业救济人数大幅上升<b>41.9万美国人首次申请失业救济</b>(远高于前一周的36.8万份和35万份的预期)...</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d8eda8482fbe99bba871d16bc5379532\" tg-width=\"980\" tg-height=\"584\" width=\"100%\" height=\"auto\"><i>Source: Bloomberg</i></p><p><blockquote><i>资料来源:彭博社</i></blockquote></p><p> Michigan and Texas saw the biggest jump in claims while New York and Oklahoma saw the best improvement...</p><p><blockquote>密歇根州和德克萨斯州的申请人数增幅最大,而纽约州和俄克拉荷马州的增幅最大...</blockquote></p><p> <img src=\"https://static.tigerbbs.com/fcb4d834111a6ca8db1254f129a11ecc\" tg-width=\"1207\" tg-height=\"1276\" width=\"100%\" height=\"auto\">'Traditional'<i>c</i>ontinuing claims were basically unchanged over the prior week's revision.</p><p><blockquote>“传统”<i>c</i>与前一周的修订相比,持续索赔基本没有变化。</blockquote></p><p> There is some good news though,<b>the total number of claims plunged by over 1.2 million last week</b>(driven by a plunge in pandemic specific aid as states began shutting off the handouts)...</p><p><blockquote>不过也有一些好消息,<b>上周索赔总数锐减超过120万</b>(由于各州开始关闭施舍,疫情特定援助大幅下降)...</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b4b991ebbb0b2782ffdd1e3059e2fc78\" tg-width=\"711\" tg-height=\"215\" width=\"100%\" height=\"auto\">But, we note that overall, there remains over 12.5 million Americans on some form of government dole...</p><p><blockquote>但是,我们注意到,总的来说,仍有超过1250万美国人领取某种形式的政府救济金...</blockquote></p><p> <img src=\"https://static.tigerbbs.com/3fe2aeac47f3bbf3eaeb7d11fd96edd3\" tg-width=\"980\" tg-height=\"586\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> <i>Source: Bloomberg</i></p><p><blockquote><i>资料来源:彭博社</i></blockquote></p><p> For context, that compares to the less than 2 million pre-pandemic-lockdowns.</p><p><blockquote>相比之下,大流行前的封锁人数不到200万。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite","SPY":"标普500ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136039581","content_text":"(July 22) U.S. initial jobless claims jump 51,000 to 419,000 in mid-July, vs. 350,000 estimate.\nTotal Number Of Americans On The Dole Plunges By 1.2 Million As States Cut Off Emergency Aid\nThis was not supposed to happen.\nInitial jobless claims jumped significantly last week as419,000 Americans filed for jobless benefits for the first time(well above the prior week's 368k and expectations of a 350k print)...\nSource: Bloomberg\nMichigan and Texas saw the biggest jump in claims while New York and Oklahoma saw the best improvement...\n'Traditional'continuing claims were basically unchanged over the prior week's revision.\nThere is some good news though,the total number of claims plunged by over 1.2 million last week(driven by a plunge in pandemic specific aid as states began shutting off the handouts)...\nBut, we note that overall, there remains over 12.5 million Americans on some form of government dole...\n\nSource: Bloomberg\nFor context, that compares to the less than 2 million pre-pandemic-lockdowns.","news_type":1,"symbols_score_info":{"SPY":0.9,".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":571,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170995780,"gmtCreate":1626398619040,"gmtModify":1633927127426,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570801892131113","idStr":"3570801892131113"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/170995780","repostId":"2151573133","repostType":4,"isVote":1,"tweetType":1,"viewCount":424,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":180277353,"gmtCreate":1623209596872,"gmtModify":1634035768362,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570801892131113","authorIdStr":"3570801892131113"},"themes":[],"htmlText":"Like and comment please","listText":"Like and comment please","text":"Like and comment please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":7,"repostSize":0,"link":"https://laohu8.com/post/180277353","repostId":"1148360854","repostType":4,"repost":{"id":"1148360854","kind":"news","pubTimestamp":1623195944,"share":"https://www.laohu8.com/m/news/1148360854?lang=zh_CN&edition=full","pubTime":"2021-06-09 07:45","market":"us","language":"en","title":"Clover Health Roars to Record as Short Sellers Get Burned<blockquote>卖空者被烧伤,三叶草健康飙升至创纪录水平</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1148360854","media":"Bloomberg","summary":"(Bloomberg) -- Clover Health Inc., a health insurer backed by venture capitalist Chamath Palihapitiy","content":"<p>(Bloomberg) -- Clover Health Inc., a health insurer backed by venture capitalist Chamath Palihapitiya, was swept up in meme-stock mania on Tuesday, posting a second day of wild gains as retail investors banded together to punish short-sellers betting against the company.</p><p><blockquote>(彭博)-由风险投资家Chamath Palihapitiya支持的健康保险公司Clover Health Inc.周二陷入了meme股票热潮,连续第二天大幅上涨,因为散户投资者联合起来惩罚做空该公司的卖空者。</blockquote></p><p>Clover rallied 86% to close at $22.15 in New York trading after briefly doubling intraday. The gains erased five months of losses in the stock -- which formed part of a broader selloff in Palihapitiya-backed companies -- in just two days. Trading volume in Clover was more than 29 times the three-month daily average on Tuesday, with a record 718 million shares changing hands.</p><p><blockquote>在盘中短暂翻倍后,Clover在纽约交易中上涨86%,收于22.15美元。这些涨幅在短短两天内抹去了该股五个月的跌幅,这是帕里哈皮蒂亚支持的公司更广泛抛售的一部分。周二,Clover的交易量是三个月日均交易量的29倍以上,换手量达到创纪录的7.18亿股。</blockquote></p><p>The sudden flurry of demand comes after retail traders realized that short-sellers had been swelling their bets against Clover, a move that left them vulnerable if the stock were to start rallying. The stock’s story -- like many retail plays -- has left behind fundamentals with shares trading above $20, that’s more than twice the average analyst estimate.</p><p><blockquote>在零售交易员意识到卖空者一直在加大对Clover的押注之后,需求突然激增,如果该股开始上涨,此举将使他们变得脆弱。与许多散户股票一样,该股的故事已经落后于基本面,股价交易价格高于20美元,是分析师平均预期的两倍多。</blockquote></p><p>On the Reddit forum WallStreetBets, chatter has built this week on the potential for a short-squeeze in the stock, following similar successful ploys on meme stocks including Workhorse Group Inc. and Richard Branson’s space exploration company Virgin Galactic Holdings Inc., which advanced 12% and 8.1%, respectively.</p><p><blockquote>在Reddit论坛WallStreetBets上,继Workhorse Group Inc.和理查德·布兰森(Richard Branson)的太空探索公司维珍银河控股公司(Virgin Galactic Holdings Inc.)等模因股票也采取了类似的成功策略后,chatter本周对该股进行了空头挤压的可能性进行了讨论。分别为12%和8.1%。</blockquote></p><p>Bearish bets in Clover have been steadily climbing since March and now stand at over $580 million or 44% of the public float, according to data from S3 Partners. Daytraders also touted the stock’s potential inclusion into the Russell indices -- a rebalancing of those benchmarks is expected toward the end of June.</p><p><blockquote>S3 Partners的数据显示,自3月份以来,对Clover的看跌押注一直在稳步攀升,目前已超过5.8亿美元,占公众持股量的44%。日内交易者还吹捧该股有可能被纳入罗素指数——预计这些基准将在6月底进行重新平衡。</blockquote></p><p>Read more: AMC, Wendy’s Lead Rally as Meme Stocks Rise for a Second Day</p><p><blockquote>阅读更多:随着模因股票连续第二天上涨,AMC、Wendy's领涨</blockquote></p><p>“Short sellers appear to be shorting into a rising market and overheated stocks, they are looking for a pullback off of these elevated levels,” said Ihor Dusaniwsky, S3’s managing director of predictive analytics.</p><p><blockquote>S3预测分析董事总经理Ihor Dusaniwsky表示:“卖空者似乎正在做空上涨的市场和过热的股票,他们正在寻求从这些高位回调。”</blockquote></p><p>Short sellers were down about $465 million on today’s move for a year-to-date loss of $517 million, he said.</p><p><blockquote>他表示,卖空者在今天的走势中下跌了约4.65亿美元,今年迄今损失了5.17亿美元。</blockquote></p><p>Clover declined to comment on the moves.</p><p><blockquote>Clover拒绝对这些举措发表评论。</blockquote></p><p>Meme Advance</p><p><blockquote>模因推进</blockquote></p><p>Other retail-trader favorites, such as AMC Entertainment Holdings Inc. and GameStop Corp., see-sawed on Tuesday amid heavy volume. Wendy’s Co., the latest addition to the retail-trader frenzy, climbed to a record amid touts on Reddit.</p><p><blockquote>AMC院线控股公司和游戏驿站公司等其他散户投资者的最爱周二在成交量巨大的情况下出现拉锯。温迪公司(Wendy's Co.)是零售商狂热的最新成员,在Reddit上的吹捧中攀升至创纪录水平。</blockquote></p><p>“The power of the network effect of social media entices more people to get involved, so then they start broadening their horizons, looking for other names that have high short interest and things like that,” said Michael O’Rourke, chief market strategist at JonesTrading.</p><p><blockquote>首席市场策略师迈克尔·奥罗克(Michael O'Rourke)表示:“社交媒体网络效应的力量吸引了更多人参与其中,因此他们开始拓宽视野,寻找其他具有高空头兴趣的公司等等。”琼斯交易。</blockquote></p><p>Before June, Clover saw its value split in half, with the once-hot market for companies brought to the market via SPACs, or blank-check companies, cooling off amid increased regulatory oversight.</p><p><blockquote>6月之前,Clover的价值被腰斩,曾经火爆的通过SPAC或空白支票公司上市的公司市场在监管力度加大的情况下降温。</blockquote></p><p>The outspoken Palihapitiya has remained undaunted. He plans to list 26 blank-check companies -- one for each letter of the alphabet -- and he kicked off with four new companies targeting the biotech sector last week. Clover is now up more than 30% for the year after a six-day winning streak.</p><p><blockquote>直言不讳的帕里哈皮蒂亚仍然无所畏惧。他计划列出26家空白支票公司——《alphabet》的每封信对应一家——上周他首先列出了四家针对生物技术行业的新公司。在连续六天上涨后,Clover今年股价上涨超过30%。</blockquote></p><p>Clover’s head, Vivek Garipalli, who started off as a daytrader two decades ago, has embraced the support from retail investors.</p><p><blockquote>Clover的负责人Vivek Garipalli二十年前以日内交易者起家,现在已经接受了散户投资者的支持。</blockquote></p><p>“We are a big believer in the retail investor community,” Garipall said on the company’s earnings call in May, one which invited Reddit users to participate.</p><p><blockquote>“我们非常相信散户投资者群体,”加里帕尔在该公司5月份的收益看涨期权上表示,该活动邀请Reddit用户参加。</blockquote></p><p>Clover shares surged more than 7% in the after hour trading.</p><p><blockquote>Clover股价在盘后交易中飙升超过7%。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Health Roars to Record as Short Sellers Get Burned<blockquote>卖空者被烧伤,三叶草健康飙升至创纪录水平</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Health Roars to Record as Short Sellers Get Burned<blockquote>卖空者被烧伤,三叶草健康飙升至创纪录水平</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-06-09 07:45</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Clover Health Inc., a health insurer backed by venture capitalist Chamath Palihapitiya, was swept up in meme-stock mania on Tuesday, posting a second day of wild gains as retail investors banded together to punish short-sellers betting against the company.</p><p><blockquote>(彭博)-由风险投资家Chamath Palihapitiya支持的健康保险公司Clover Health Inc.周二陷入了meme股票热潮,连续第二天大幅上涨,因为散户投资者联合起来惩罚做空该公司的卖空者。</blockquote></p><p>Clover rallied 86% to close at $22.15 in New York trading after briefly doubling intraday. The gains erased five months of losses in the stock -- which formed part of a broader selloff in Palihapitiya-backed companies -- in just two days. Trading volume in Clover was more than 29 times the three-month daily average on Tuesday, with a record 718 million shares changing hands.</p><p><blockquote>在盘中短暂翻倍后,Clover在纽约交易中上涨86%,收于22.15美元。这些涨幅在短短两天内抹去了该股五个月的跌幅,这是帕里哈皮蒂亚支持的公司更广泛抛售的一部分。周二,Clover的交易量是三个月日均交易量的29倍以上,换手量达到创纪录的7.18亿股。</blockquote></p><p>The sudden flurry of demand comes after retail traders realized that short-sellers had been swelling their bets against Clover, a move that left them vulnerable if the stock were to start rallying. The stock’s story -- like many retail plays -- has left behind fundamentals with shares trading above $20, that’s more than twice the average analyst estimate.</p><p><blockquote>在零售交易员意识到卖空者一直在加大对Clover的押注之后,需求突然激增,如果该股开始上涨,此举将使他们变得脆弱。与许多散户股票一样,该股的故事已经落后于基本面,股价交易价格高于20美元,是分析师平均预期的两倍多。</blockquote></p><p>On the Reddit forum WallStreetBets, chatter has built this week on the potential for a short-squeeze in the stock, following similar successful ploys on meme stocks including Workhorse Group Inc. and Richard Branson’s space exploration company Virgin Galactic Holdings Inc., which advanced 12% and 8.1%, respectively.</p><p><blockquote>在Reddit论坛WallStreetBets上,继Workhorse Group Inc.和理查德·布兰森(Richard Branson)的太空探索公司维珍银河控股公司(Virgin Galactic Holdings Inc.)等模因股票也采取了类似的成功策略后,chatter本周对该股进行了空头挤压的可能性进行了讨论。分别为12%和8.1%。</blockquote></p><p>Bearish bets in Clover have been steadily climbing since March and now stand at over $580 million or 44% of the public float, according to data from S3 Partners. Daytraders also touted the stock’s potential inclusion into the Russell indices -- a rebalancing of those benchmarks is expected toward the end of June.</p><p><blockquote>S3 Partners的数据显示,自3月份以来,对Clover的看跌押注一直在稳步攀升,目前已超过5.8亿美元,占公众持股量的44%。日内交易者还吹捧该股有可能被纳入罗素指数——预计这些基准将在6月底进行重新平衡。</blockquote></p><p>Read more: AMC, Wendy’s Lead Rally as Meme Stocks Rise for a Second Day</p><p><blockquote>阅读更多:随着模因股票连续第二天上涨,AMC、Wendy's领涨</blockquote></p><p>“Short sellers appear to be shorting into a rising market and overheated stocks, they are looking for a pullback off of these elevated levels,” said Ihor Dusaniwsky, S3’s managing director of predictive analytics.</p><p><blockquote>S3预测分析董事总经理Ihor Dusaniwsky表示:“卖空者似乎正在做空上涨的市场和过热的股票,他们正在寻求从这些高位回调。”</blockquote></p><p>Short sellers were down about $465 million on today’s move for a year-to-date loss of $517 million, he said.</p><p><blockquote>他表示,卖空者在今天的走势中下跌了约4.65亿美元,今年迄今损失了5.17亿美元。</blockquote></p><p>Clover declined to comment on the moves.</p><p><blockquote>Clover拒绝对这些举措发表评论。</blockquote></p><p>Meme Advance</p><p><blockquote>模因推进</blockquote></p><p>Other retail-trader favorites, such as AMC Entertainment Holdings Inc. and GameStop Corp., see-sawed on Tuesday amid heavy volume. Wendy’s Co., the latest addition to the retail-trader frenzy, climbed to a record amid touts on Reddit.</p><p><blockquote>AMC院线控股公司和游戏驿站公司等其他散户投资者的最爱周二在成交量巨大的情况下出现拉锯。温迪公司(Wendy's Co.)是零售商狂热的最新成员,在Reddit上的吹捧中攀升至创纪录水平。</blockquote></p><p>“The power of the network effect of social media entices more people to get involved, so then they start broadening their horizons, looking for other names that have high short interest and things like that,” said Michael O’Rourke, chief market strategist at JonesTrading.</p><p><blockquote>首席市场策略师迈克尔·奥罗克(Michael O'Rourke)表示:“社交媒体网络效应的力量吸引了更多人参与其中,因此他们开始拓宽视野,寻找其他具有高空头兴趣的公司等等。”琼斯交易。</blockquote></p><p>Before June, Clover saw its value split in half, with the once-hot market for companies brought to the market via SPACs, or blank-check companies, cooling off amid increased regulatory oversight.</p><p><blockquote>6月之前,Clover的价值被腰斩,曾经火爆的通过SPAC或空白支票公司上市的公司市场在监管力度加大的情况下降温。</blockquote></p><p>The outspoken Palihapitiya has remained undaunted. He plans to list 26 blank-check companies -- one for each letter of the alphabet -- and he kicked off with four new companies targeting the biotech sector last week. Clover is now up more than 30% for the year after a six-day winning streak.</p><p><blockquote>直言不讳的帕里哈皮蒂亚仍然无所畏惧。他计划列出26家空白支票公司——《alphabet》的每封信对应一家——上周他首先列出了四家针对生物技术行业的新公司。在连续六天上涨后,Clover今年股价上涨超过30%。</blockquote></p><p>Clover’s head, Vivek Garipalli, who started off as a daytrader two decades ago, has embraced the support from retail investors.</p><p><blockquote>Clover的负责人Vivek Garipalli二十年前以日内交易者起家,现在已经接受了散户投资者的支持。</blockquote></p><p>“We are a big believer in the retail investor community,” Garipall said on the company’s earnings call in May, one which invited Reddit users to participate.</p><p><blockquote>“我们非常相信散户投资者群体,”加里帕尔在该公司5月份的收益看涨期权上表示,该活动邀请Reddit用户参加。</blockquote></p><p>Clover shares surged more than 7% in the after hour trading.</p><p><blockquote>Clover股价在盘后交易中飙升超过7%。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://finance.yahoo.com/news/palihapitiya-clover-roars-record-short-143312310.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://finance.yahoo.com/news/palihapitiya-clover-roars-record-short-143312310.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148360854","content_text":"(Bloomberg) -- Clover Health Inc., a health insurer backed by venture capitalist Chamath Palihapitiya, was swept up in meme-stock mania on Tuesday, posting a second day of wild gains as retail investors banded together to punish short-sellers betting against the company.Clover rallied 86% to close at $22.15 in New York trading after briefly doubling intraday. The gains erased five months of losses in the stock -- which formed part of a broader selloff in Palihapitiya-backed companies -- in just two days. Trading volume in Clover was more than 29 times the three-month daily average on Tuesday, with a record 718 million shares changing hands.The sudden flurry of demand comes after retail traders realized that short-sellers had been swelling their bets against Clover, a move that left them vulnerable if the stock were to start rallying. The stock’s story -- like many retail plays -- has left behind fundamentals with shares trading above $20, that’s more than twice the average analyst estimate.On the Reddit forum WallStreetBets, chatter has built this week on the potential for a short-squeeze in the stock, following similar successful ploys on meme stocks including Workhorse Group Inc. and Richard Branson’s space exploration company Virgin Galactic Holdings Inc., which advanced 12% and 8.1%, respectively.Bearish bets in Clover have been steadily climbing since March and now stand at over $580 million or 44% of the public float, according to data from S3 Partners. Daytraders also touted the stock’s potential inclusion into the Russell indices -- a rebalancing of those benchmarks is expected toward the end of June.Read more: AMC, Wendy’s Lead Rally as Meme Stocks Rise for a Second Day“Short sellers appear to be shorting into a rising market and overheated stocks, they are looking for a pullback off of these elevated levels,” said Ihor Dusaniwsky, S3’s managing director of predictive analytics.Short sellers were down about $465 million on today’s move for a year-to-date loss of $517 million, he said.Clover declined to comment on the moves.Meme AdvanceOther retail-trader favorites, such as AMC Entertainment Holdings Inc. and GameStop Corp., see-sawed on Tuesday amid heavy volume. Wendy’s Co., the latest addition to the retail-trader frenzy, climbed to a record amid touts on Reddit.“The power of the network effect of social media entices more people to get involved, so then they start broadening their horizons, looking for other names that have high short interest and things like that,” said Michael O’Rourke, chief market strategist at JonesTrading.Before June, Clover saw its value split in half, with the once-hot market for companies brought to the market via SPACs, or blank-check companies, cooling off amid increased regulatory oversight.The outspoken Palihapitiya has remained undaunted. He plans to list 26 blank-check companies -- one for each letter of the alphabet -- and he kicked off with four new companies targeting the biotech sector last week. Clover is now up more than 30% for the year after a six-day winning streak.Clover’s head, Vivek Garipalli, who started off as a daytrader two decades ago, has embraced the support from retail investors.“We are a big believer in the retail investor community,” Garipall said on the company’s earnings call in May, one which invited Reddit users to participate.Clover shares surged more than 7% in the after hour trading.","news_type":1,"symbols_score_info":{"CLOV":0.9}},"isVote":1,"tweetType":1,"viewCount":383,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":358116849,"gmtCreate":1616672612181,"gmtModify":1634524638544,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570801892131113","authorIdStr":"3570801892131113"},"themes":[],"htmlText":"Help like and commetn","listText":"Help like and commetn","text":"Help like and commetn","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/358116849","repostId":"1141704232","repostType":4,"isVote":1,"tweetType":1,"viewCount":488,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":350754311,"gmtCreate":1616293489233,"gmtModify":1634526475425,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570801892131113","authorIdStr":"3570801892131113"},"themes":[],"htmlText":"Help like and comment please","listText":"Help like and comment please","text":"Help like and comment please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/350754311","repostId":"1106180509","repostType":4,"isVote":1,"tweetType":1,"viewCount":631,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126468342,"gmtCreate":1624582006886,"gmtModify":1633951012129,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570801892131113","authorIdStr":"3570801892131113"},"themes":[],"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/126468342","repostId":"2146255080","repostType":4,"isVote":1,"tweetType":1,"viewCount":476,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":117301771,"gmtCreate":1623115563193,"gmtModify":1634036791181,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570801892131113","authorIdStr":"3570801892131113"},"themes":[],"htmlText":"Like and comment please","listText":"Like and comment please","text":"Like and comment please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/117301771","repostId":"2141342255","repostType":4,"isVote":1,"tweetType":1,"viewCount":385,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":354240970,"gmtCreate":1617182131290,"gmtModify":1634522225766,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570801892131113","authorIdStr":"3570801892131113"},"themes":[],"htmlText":"Help comment please","listText":"Help comment please","text":"Help comment please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/354240970","repostId":"1192097345","repostType":4,"repost":{"id":"1192097345","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1617178375,"share":"https://www.laohu8.com/m/news/1192097345?lang=zh_CN&edition=full","pubTime":"2021-03-31 16:12","market":"sh","language":"en","title":"Huawei: FY2020 income of 64.6billion yuan(+3.2% Y/Y)<blockquote>华为:2020财年收入646亿元(同比增长3.2%)</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1192097345","media":"Tiger Newspress","summary":"(March 31) China's Huawei Technologies reported modest annual profit growth for 2020 as overseas rev","content":"<p>(March 31) China's Huawei Technologies reported modest annual profit growth for 2020 as overseas revenues declined due to disruption caused by the pandemic and the company's placement on a U.S. export blacklist.</p><p><blockquote>(3月31日)中国华为技术公司(Huawei Technologies)报告称,由于疫情造成的干扰以及该公司被列入美国出口黑名单,海外收入下降,2020年年度利润略有增长。</blockquote></p><p>Net profit for 2020 came in at 64.6 billion yuan ($9.83 billion), up 3.2%, compared to growth of 5.6% a year earlier.</p><p><blockquote>2020年净利润为646亿元人民币(98.3亿美元),增长3.2%,而上年同期增长5.6%。</blockquote></p><p>Huawei was put on an export blacklist by former U.S. President Donald Trump in 2019 and barred from accessing critical technology of U.S. origin, affecting its ability to design its own chips and source components from outside vendors.</p><p><blockquote>华为于2019年被美国前总统唐纳德·特朗普列入出口黑名单,并被禁止获得原产于美国的关键技术,影响了其设计自己芯片和从外部供应商采购组件的能力。</blockquote></p><p>The ban put Huawei's handset business under immense pressure, with the company selling off its budget smartphone unit to a consortium of agents and dealers in November 2020 to keep it alive.</p><p><blockquote>该禁令使华为的手机业务面临巨大压力,该公司于2020年11月将其廉价智能手机部门出售给了一个代理商和经销商财团,以维持其生存。</blockquote></p><p>Yet Huawei reported that its consumer business, which includes smartphones, brought in 482.9 billion yuan, up 3.3% year on year, and accounted for over half of the company's revenue.</p><p><blockquote>然而,华为报告称,包括智能手机在内的消费者业务收入为4829亿元人民币,同比增长3.3%,占公司收入的一半以上。</blockquote></p><p>The rise in part was thanks to growth in devices such as smartwatches and laptops, a Huawei spokesman said.</p><p><blockquote>华为发言人表示,这一增长部分归功于智能手表和笔记本电脑等设备的增长。</blockquote></p><p>The company's carrier business, which includes 5G network equipment, brought in 302.6 billion yuan, an increase of just 0.2% a year earlier.</p><p><blockquote>该公司包括5G网络设备在内的运营商业务收入为3026亿元,同比仅增长0.2%。</blockquote></p><p>Huawei's growth was driven by its home market, with revenue in China up by 15.4% to 584.9 billion yuan.</p><p><blockquote>华为的增长受到国内市场的推动,在中国的收入增长了15.4%,达到5849亿元。</blockquote></p><p>Its business declined everywhere else, with revenues down 12.2% to 180.8 billion yuan in Europe, the Middle East and Africa, down 8.7% to 64.4 billion yuan in the rest of Asia, and down 24.5% to 39.6 billion yuan from the Americas.</p><p><blockquote>其在其他地区的业务均出现下滑,欧洲、中东和非洲的收入下降12.2%至1808亿元人民币,亚洲其他地区的收入下降8.7%至644亿元人民币,美洲的收入下降24.5%至396亿元人民币。</blockquote></p><p>Revenue from the company's enterprise segment soared 23% year on year to 100.3 billion yuan, although it still makes the smallest in revenue of the three business groups.</p><p><blockquote>该公司企业部门的收入同比飙升23%至1003亿元,尽管仍是三个业务集团中收入最小的。</blockquote></p><p>The company invested 141.9 billion yuan in R&D spending in 2020, up from 131.7 billion yuan a year earlier.</p><p><blockquote>公司2020年研发支出投入1419亿元,高于上年同期的1317亿元。</blockquote></p><p>Huawei's cash flow from operating activities was 35.2 billion yuan, down by 61.5% on a year earlier.</p><p><blockquote>华为经营活动现金流352亿元,同比下降61.5%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Huawei: FY2020 income of 64.6billion yuan(+3.2% Y/Y)<blockquote>华为:2020财年收入646亿元(同比增长3.2%)</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHuawei: FY2020 income of 64.6billion yuan(+3.2% Y/Y)<blockquote>华为:2020财年收入646亿元(同比增长3.2%)</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-03-31 16:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(March 31) China's Huawei Technologies reported modest annual profit growth for 2020 as overseas revenues declined due to disruption caused by the pandemic and the company's placement on a U.S. export blacklist.</p><p><blockquote>(3月31日)中国华为技术公司(Huawei Technologies)报告称,由于疫情造成的干扰以及该公司被列入美国出口黑名单,海外收入下降,2020年年度利润略有增长。</blockquote></p><p>Net profit for 2020 came in at 64.6 billion yuan ($9.83 billion), up 3.2%, compared to growth of 5.6% a year earlier.</p><p><blockquote>2020年净利润为646亿元人民币(98.3亿美元),增长3.2%,而上年同期增长5.6%。</blockquote></p><p>Huawei was put on an export blacklist by former U.S. President Donald Trump in 2019 and barred from accessing critical technology of U.S. origin, affecting its ability to design its own chips and source components from outside vendors.</p><p><blockquote>华为于2019年被美国前总统唐纳德·特朗普列入出口黑名单,并被禁止获得原产于美国的关键技术,影响了其设计自己芯片和从外部供应商采购组件的能力。</blockquote></p><p>The ban put Huawei's handset business under immense pressure, with the company selling off its budget smartphone unit to a consortium of agents and dealers in November 2020 to keep it alive.</p><p><blockquote>该禁令使华为的手机业务面临巨大压力,该公司于2020年11月将其廉价智能手机部门出售给了一个代理商和经销商财团,以维持其生存。</blockquote></p><p>Yet Huawei reported that its consumer business, which includes smartphones, brought in 482.9 billion yuan, up 3.3% year on year, and accounted for over half of the company's revenue.</p><p><blockquote>然而,华为报告称,包括智能手机在内的消费者业务收入为4829亿元人民币,同比增长3.3%,占公司收入的一半以上。</blockquote></p><p>The rise in part was thanks to growth in devices such as smartwatches and laptops, a Huawei spokesman said.</p><p><blockquote>华为发言人表示,这一增长部分归功于智能手表和笔记本电脑等设备的增长。</blockquote></p><p>The company's carrier business, which includes 5G network equipment, brought in 302.6 billion yuan, an increase of just 0.2% a year earlier.</p><p><blockquote>该公司包括5G网络设备在内的运营商业务收入为3026亿元,同比仅增长0.2%。</blockquote></p><p>Huawei's growth was driven by its home market, with revenue in China up by 15.4% to 584.9 billion yuan.</p><p><blockquote>华为的增长受到国内市场的推动,在中国的收入增长了15.4%,达到5849亿元。</blockquote></p><p>Its business declined everywhere else, with revenues down 12.2% to 180.8 billion yuan in Europe, the Middle East and Africa, down 8.7% to 64.4 billion yuan in the rest of Asia, and down 24.5% to 39.6 billion yuan from the Americas.</p><p><blockquote>其在其他地区的业务均出现下滑,欧洲、中东和非洲的收入下降12.2%至1808亿元人民币,亚洲其他地区的收入下降8.7%至644亿元人民币,美洲的收入下降24.5%至396亿元人民币。</blockquote></p><p>Revenue from the company's enterprise segment soared 23% year on year to 100.3 billion yuan, although it still makes the smallest in revenue of the three business groups.</p><p><blockquote>该公司企业部门的收入同比飙升23%至1003亿元,尽管仍是三个业务集团中收入最小的。</blockquote></p><p>The company invested 141.9 billion yuan in R&D spending in 2020, up from 131.7 billion yuan a year earlier.</p><p><blockquote>公司2020年研发支出投入1419亿元,高于上年同期的1317亿元。</blockquote></p><p>Huawei's cash flow from operating activities was 35.2 billion yuan, down by 61.5% on a year earlier.</p><p><blockquote>华为经营活动现金流352亿元,同比下降61.5%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/a7265a90bb3065920567e79d1fb73485","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192097345","content_text":"(March 31) China's Huawei Technologies reported modest annual profit growth for 2020 as overseas revenues declined due to disruption caused by the pandemic and the company's placement on a U.S. export blacklist.Net profit for 2020 came in at 64.6 billion yuan ($9.83 billion), up 3.2%, compared to growth of 5.6% a year earlier.Huawei was put on an export blacklist by former U.S. President Donald Trump in 2019 and barred from accessing critical technology of U.S. origin, affecting its ability to design its own chips and source components from outside vendors.The ban put Huawei's handset business under immense pressure, with the company selling off its budget smartphone unit to a consortium of agents and dealers in November 2020 to keep it alive.Yet Huawei reported that its consumer business, which includes smartphones, brought in 482.9 billion yuan, up 3.3% year on year, and accounted for over half of the company's revenue.The rise in part was thanks to growth in devices such as smartwatches and laptops, a Huawei spokesman said.The company's carrier business, which includes 5G network equipment, brought in 302.6 billion yuan, an increase of just 0.2% a year earlier.Huawei's growth was driven by its home market, with revenue in China up by 15.4% to 584.9 billion yuan.Its business declined everywhere else, with revenues down 12.2% to 180.8 billion yuan in Europe, the Middle East and Africa, down 8.7% to 64.4 billion yuan in the rest of Asia, and down 24.5% to 39.6 billion yuan from the Americas.Revenue from the company's enterprise segment soared 23% year on year to 100.3 billion yuan, although it still makes the smallest in revenue of the three business groups.The company invested 141.9 billion yuan in R&D spending in 2020, up from 131.7 billion yuan a year earlier.Huawei's cash flow from operating activities was 35.2 billion yuan, down by 61.5% on a year earlier.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":553,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":328763207,"gmtCreate":1615560341509,"gmtModify":1703490947696,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570801892131113","authorIdStr":"3570801892131113"},"themes":[],"htmlText":"Help like and comment please","listText":"Help like and comment please","text":"Help like and comment please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/328763207","repostId":"1122088806","repostType":4,"isVote":1,"tweetType":1,"viewCount":509,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":891121937,"gmtCreate":1628351635729,"gmtModify":1633751503672,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570801892131113","authorIdStr":"3570801892131113"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/891121937","repostId":"1139912651","repostType":4,"isVote":1,"tweetType":1,"viewCount":636,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":359144593,"gmtCreate":1616377370512,"gmtModify":1634526178792,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570801892131113","authorIdStr":"3570801892131113"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/359144593","repostId":"1111376117","repostType":4,"isVote":1,"tweetType":1,"viewCount":724,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":325997002,"gmtCreate":1615855863206,"gmtModify":1703493999690,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570801892131113","authorIdStr":"3570801892131113"},"themes":[],"htmlText":"Help like and comment","listText":"Help like and comment","text":"Help like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/325997002","repostId":"1151746119","repostType":4,"isVote":1,"tweetType":1,"viewCount":390,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890033622,"gmtCreate":1628065255566,"gmtModify":1633753919051,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570801892131113","authorIdStr":"3570801892131113"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/890033622","repostId":"1124757232","repostType":4,"repost":{"id":"1124757232","kind":"news","pubTimestamp":1628045612,"share":"https://www.laohu8.com/m/news/1124757232?lang=zh_CN&edition=full","pubTime":"2021-08-04 10:53","market":"us","language":"en","title":"3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1124757232","media":"The Motley Fool","summary":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfi","content":"<p><b><i>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.</i></b></p><p><blockquote><b><i>这就是为什么辉瑞、Inari Medical和Novavax的股票在2021年可能更有价值。</i></b></blockquote></p><p> <b>Key Points</b></p><p><blockquote><b>要点</b></blockquote></p><p> <ul> <li>Pfizer might surprise to the upside.</li> <li>Inari Medical is growing like gangbusters.</li> <li>Novavax's vaccine might be an important booster shot as the COVID-19 virus mutates.</li> </ul> COVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?</p><p><blockquote><ul><li>辉瑞可能会带来惊喜。</li><li>伊那里医疗公司正在飞速发展。</li><li>随着COVID-19病毒的变异,Novavax的疫苗可能是一剂重要的加强针。</li></ul>2020年,新冠肺炎和国际封锁导致世界经济崩溃。许多人已经接种了疫苗,并期待正常化。但COVID正在变异,新的德尔塔变异毒株可能会给世界的重新开放带来麻烦。投资者如何保护自己?</blockquote></p><p> A panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">Inari Medical, Inc.</a></b>, and <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</p><p><blockquote>Motley Fool撰稿人小组为医疗保健股提供了三个想法,即使新冠疫情形势恶化,这些股票也将在2021年飙升。阅读更多内容,了解为什么您可能想购买<b><a href=\"https://laohu8.com/S/PFE\">辉瑞</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">伊那里医疗公司。</a></b>,和<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f3ed6a343e35e121aafbaa2b30134955\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源:盖蒂图片社。</span></p></blockquote></p><p> <h3><b>Pfizer: More room to run</b></h3> <b>George Budwell</b> <b>(Pfizer):</b> American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> -- losing steam from a sales perspective starting in 2022.</p><p><blockquote><h3><b>辉瑞:更多运行空间</b></h3><b>乔治·布德维尔</b> <b>(辉瑞):</b>在目前的新冠疫苗公司中,美国制药巨头辉瑞听起来可能不是一个性感的选择。华尔街目前的共识是制药商Comirnaty的疫苗——与<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>——从2022年开始,从销售角度来看失去动力。</blockquote></p><p> Because of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.</p><p><blockquote>然而,由于德尔塔变异毒株,Comirnaty的商业寿命可能会比最初预期的长得多。虽然高传播变种的出现对整个社会来说显然是个坏消息,但辉瑞及其股东可能会从这一不幸的发展中受益。</blockquote></p><p> There are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company announced that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.</p><p><blockquote>有两个明显的理由认为辉瑞的股价可能会因达美航空问题而走高。首先,该公司宣布,最早可能在本月提交第三次加强注射的紧急使用授权。其次,辉瑞计划本月启动德尔塔特异性版本疫苗的临床试验。</blockquote></p><p> Although the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.</p><p><blockquote>尽管美国食品药品监督管理局和疾病控制与预防中心最近都淡化了加强注射的必要性,但辉瑞已经提出了第三次注射的令人信服的理由,以应对德尔塔变异毒株的猖獗传播和Comirnaty在完全接种疫苗后6至12个月的疗效减弱。</blockquote></p><p> The big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.</p><p><blockquote>对于投资者来说,总体情况是,辉瑞2022年的收入可能比2021年增长9.7%——也就是说,如果加强注射确实获得批准,并且该公司还成功开发了delta特异性疫苗。相比之下,华尔街目前预计该制药商明年的营收将比2021年下降14.8%。</blockquote></p><p> Where is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a dividend-paying big pharma stock.</p><p><blockquote>辉瑞的股票可能走向何方?从保守的角度来看,如果疫苗方面的所有部分都到位,股价应该会达到50美元。这比该制药商的股价目前上涨了大约17%,甚至还没有考虑到该公司当前水平上颇具吸引力的3.64%股息收益率。简而言之,如果这种情况实现,辉瑞的股票交易价格将仅为2022年销售额的约3.5倍,对于派息的大型制药股来说,这是一个相当适中的估值。</blockquote></p><p> <h3><b>Inari Medical: Skyrocketing Sales</b></h3> <b>Patrick Bafuma</b> <b>(Inari Medical):</b> If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to <i>The New York Times</i> -- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.</p><p><blockquote><h3><b>伊那里医疗:销售额暴涨</b></h3><b>帕特里克·巴富马</b> <b>(伊那里医疗):</b>如果您正在寻找一只在大流行的顺风消退后具有持久力的股票,请关注伊那里医疗。数据显示,2021年7月27日新增108,000例新冠病例,为2021年2月5日以来最多<i>纽约时报</i>——这个数字是7月初7天平均水平的八倍多。更糟糕的是,COVID不仅会导致呼吸困难,还会使患者患致残和可能危及生命的血栓的风险增加两倍以上。我们仍然不确定当患者无症状或轻度COVID感染时,接种疫苗是否能完全降低血栓的风险。</blockquote></p><p></p><p> This seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021, up 130% from the same quarter last year and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according to<i>The Times</i>, Inari is likely to see an uptick in eligible cases.</p><p><blockquote>对于一家商业阶段的医疗技术公司来说,这似乎是一个很好的设置,该公司开发了微创产品,旨在消除大血凝块,而不需要强大的血栓破坏药物。通过使用ClotTriever和FlowTriever设备,伊那里迄今已治疗了25,000多名患者。2021年第一季度,临床医生使用该公司的设备进行了约5,500次手术,比去年同季度增长130%,比2020年第四季度增长约20%。根据数据,截至7月27日,美国约有12%的新冠肺炎患者出现血栓,约有35,000人因新冠肺炎住院(并且还在增加)<i>纽约时报</i>,伊那里可能会看到符合条件的病例增加。</blockquote></p><p> Not to mention the company's results thus far for blood clots in the lung are spectacular:</p><p><blockquote>更不用说该公司迄今为止在肺部血栓方面的结果非常惊人:</blockquote></p><p> <ul> <li>With the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.</li> <li>There's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.</li> <li>Major adverse events within 48 hours occur at only a 1.3% rate.</li> <li>No ICU stays are required after the procedure.</li> </ul> Add it all up, and Inari's retrieval device seems like an obvious choice.</p><p><blockquote><ul><li>由于肺部中高风险血栓的历史30天死亡率为9.7%,伊那里0.4%的30天死亡率令人印象深刻。</li><li>30天再入院率降低了6.7%,而常规护理为24.4%。</li><li>48小时内的主要不良事件发生率仅为1.3%。</li><li>手术后不需要住ICU。</li></ul>所有这些加起来,伊那里的检索设备似乎是一个显而易见的选择。</blockquote></p><p> The company grew first-quarter revenue at 113% year over year, and 18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.</p><p><blockquote>该公司第一季度收入同比增长113%,环比增长18%,2021年第一季度毛利率为91.9%。因此,伊那里的市销率为18,使其成为一只正在出售的成长型股票。</blockquote></p><p> Inari has less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.</p><p><blockquote>Inari在价值38亿美元的美国市场的渗透率不到5%,今年早些时候在欧洲推出的市场也有很大的增长空间。这意味着这家市值45亿美元的公司有很多机会。虽然COVID影响了许多选择性和半选择性程序,但它显然没有减缓伊那里,甚至可能加速其吸收。</blockquote></p><p> <h3><b>Novavax: How high can it go?</b></h3> <b>Taylor Carmichael</b> <b>(Novavax):</b> The vaccine biotech Novavax had an amazing 2020, with its share price running up 2,700% on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.</p><p><blockquote><h3><b>Novavax:能涨到多高?</b></h3><b>泰勒·卡迈克尔</b> <b>(诺瓦瓦克斯):</b>疫苗生物技术公司Novavax在2020年表现出色,由于对其COVID疫苗的乐观情绪,其股价上涨了2700%。虽然该公司尚未申请紧急使用授权,但预计将在本季度申请。2021年迄今为止,该股已上涨60%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e7829d99a76c48579ba01c6e55fe14f\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>NVAX DATA BY YCHARTS.</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCHARTS提供的NVAX数据。</span></p></blockquote></p><p> Positive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.</p><p><blockquote>COVID-19疫苗第三阶段的积极数据导致该股在今年年初飙升,但由于该公司的疫苗上市延迟,股价已经回落。首先,制造疫苗所需的原材料短缺。现在,该公司必须证明其各种合同生产设施将保持所有地点的疫苗质量一致。</blockquote></p><p> Despite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.</p><p><blockquote>尽管存在这些延迟,但长期投资者有理由看涨。制造业正在扩大规模,预计到第三季度末,生产率将达到每月1亿剂,到12月将达到每月1.5亿剂。虽然美国的许多人已经接种了疫苗,但世界其他地方的机会相当大。Novavax已向COVAX(国际疫苗联盟)预售了11亿剂疫苗,并已签约在全球范围内供应数亿剂疫苗。</blockquote></p><p> In the U.S., the Novavax vaccine might primarily be used as a booster shot for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told <i>The New York Times</i>.</p><p><blockquote>在美国,Novavax疫苗可能主要用于已经接种疫苗的人的加强注射。FDA代理首席科学家露丝安娜·博里奥(Luciana Borio)博士表示:“它们可能确实适合加强剂。”从2015年到2017年,告诉<i>纽约时报</i>.</blockquote></p><p> Down the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.</p><p><blockquote>未来,Novavax计划将其新冠疫苗与流感疫苗结合起来,形成一种一次性疗法。虽然COVID的变异速度不如流感,但我们在过去一年中已经看到了几种变异毒株。在未来的几年里,我们很可能需要不止一次接种疫苗。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Could Soar Higher<blockquote>3只可能飙升的新冠股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Motley Fool</strong><span class=\"h-time small\">2021-08-04 10:53</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b><i>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.</i></b></p><p><blockquote><b><i>这就是为什么辉瑞、Inari Medical和Novavax的股票在2021年可能更有价值。</i></b></blockquote></p><p> <b>Key Points</b></p><p><blockquote><b>要点</b></blockquote></p><p> <ul> <li>Pfizer might surprise to the upside.</li> <li>Inari Medical is growing like gangbusters.</li> <li>Novavax's vaccine might be an important booster shot as the COVID-19 virus mutates.</li> </ul> COVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?</p><p><blockquote><ul><li>辉瑞可能会带来惊喜。</li><li>伊那里医疗公司正在飞速发展。</li><li>随着COVID-19病毒的变异,Novavax的疫苗可能是一剂重要的加强针。</li></ul>2020年,新冠肺炎和国际封锁导致世界经济崩溃。许多人已经接种了疫苗,并期待正常化。但COVID正在变异,新的德尔塔变异毒株可能会给世界的重新开放带来麻烦。投资者如何保护自己?</blockquote></p><p> A panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">Inari Medical, Inc.</a></b>, and <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</p><p><blockquote>Motley Fool撰稿人小组为医疗保健股提供了三个想法,即使新冠疫情形势恶化,这些股票也将在2021年飙升。阅读更多内容,了解为什么您可能想购买<b><a href=\"https://laohu8.com/S/PFE\">辉瑞</a></b>, <b><a href=\"https://laohu8.com/S/NARI\">伊那里医疗公司。</a></b>,和<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f3ed6a343e35e121aafbaa2b30134955\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源:盖蒂图片社。</span></p></blockquote></p><p> <h3><b>Pfizer: More room to run</b></h3> <b>George Budwell</b> <b>(Pfizer):</b> American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> -- losing steam from a sales perspective starting in 2022.</p><p><blockquote><h3><b>辉瑞:更多运行空间</b></h3><b>乔治·布德维尔</b> <b>(辉瑞):</b>在目前的新冠疫苗公司中,美国制药巨头辉瑞听起来可能不是一个性感的选择。华尔街目前的共识是制药商Comirnaty的疫苗——与<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>——从2022年开始,从销售角度来看失去动力。</blockquote></p><p> Because of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.</p><p><blockquote>然而,由于德尔塔变异毒株,Comirnaty的商业寿命可能会比最初预期的长得多。虽然高传播变种的出现对整个社会来说显然是个坏消息,但辉瑞及其股东可能会从这一不幸的发展中受益。</blockquote></p><p> There are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company announced that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.</p><p><blockquote>有两个明显的理由认为辉瑞的股价可能会因达美航空问题而走高。首先,该公司宣布,最早可能在本月提交第三次加强注射的紧急使用授权。其次,辉瑞计划本月启动德尔塔特异性版本疫苗的临床试验。</blockquote></p><p> Although the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.</p><p><blockquote>尽管美国食品药品监督管理局和疾病控制与预防中心最近都淡化了加强注射的必要性,但辉瑞已经提出了第三次注射的令人信服的理由,以应对德尔塔变异毒株的猖獗传播和Comirnaty在完全接种疫苗后6至12个月的疗效减弱。</blockquote></p><p> The big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.</p><p><blockquote>对于投资者来说,总体情况是,辉瑞2022年的收入可能比2021年增长9.7%——也就是说,如果加强注射确实获得批准,并且该公司还成功开发了delta特异性疫苗。相比之下,华尔街目前预计该制药商明年的营收将比2021年下降14.8%。</blockquote></p><p> Where is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a dividend-paying big pharma stock.</p><p><blockquote>辉瑞的股票可能走向何方?从保守的角度来看,如果疫苗方面的所有部分都到位,股价应该会达到50美元。这比该制药商的股价目前上涨了大约17%,甚至还没有考虑到该公司当前水平上颇具吸引力的3.64%股息收益率。简而言之,如果这种情况实现,辉瑞的股票交易价格将仅为2022年销售额的约3.5倍,对于派息的大型制药股来说,这是一个相当适中的估值。</blockquote></p><p> <h3><b>Inari Medical: Skyrocketing Sales</b></h3> <b>Patrick Bafuma</b> <b>(Inari Medical):</b> If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to <i>The New York Times</i> -- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.</p><p><blockquote><h3><b>伊那里医疗:销售额暴涨</b></h3><b>帕特里克·巴富马</b> <b>(伊那里医疗):</b>如果您正在寻找一只在大流行的顺风消退后具有持久力的股票,请关注伊那里医疗。数据显示,2021年7月27日新增108,000例新冠病例,为2021年2月5日以来最多<i>纽约时报</i>——这个数字是7月初7天平均水平的八倍多。更糟糕的是,COVID不仅会导致呼吸困难,还会使患者患致残和可能危及生命的血栓的风险增加两倍以上。我们仍然不确定当患者无症状或轻度COVID感染时,接种疫苗是否能完全降低血栓的风险。</blockquote></p><p></p><p> This seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021, up 130% from the same quarter last year and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according to<i>The Times</i>, Inari is likely to see an uptick in eligible cases.</p><p><blockquote>对于一家商业阶段的医疗技术公司来说,这似乎是一个很好的设置,该公司开发了微创产品,旨在消除大血凝块,而不需要强大的血栓破坏药物。通过使用ClotTriever和FlowTriever设备,伊那里迄今已治疗了25,000多名患者。2021年第一季度,临床医生使用该公司的设备进行了约5,500次手术,比去年同季度增长130%,比2020年第四季度增长约20%。根据数据,截至7月27日,美国约有12%的新冠肺炎患者出现血栓,约有35,000人因新冠肺炎住院(并且还在增加)<i>纽约时报</i>,伊那里可能会看到符合条件的病例增加。</blockquote></p><p> Not to mention the company's results thus far for blood clots in the lung are spectacular:</p><p><blockquote>更不用说该公司迄今为止在肺部血栓方面的结果非常惊人:</blockquote></p><p> <ul> <li>With the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.</li> <li>There's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.</li> <li>Major adverse events within 48 hours occur at only a 1.3% rate.</li> <li>No ICU stays are required after the procedure.</li> </ul> Add it all up, and Inari's retrieval device seems like an obvious choice.</p><p><blockquote><ul><li>由于肺部中高风险血栓的历史30天死亡率为9.7%,伊那里0.4%的30天死亡率令人印象深刻。</li><li>30天再入院率降低了6.7%,而常规护理为24.4%。</li><li>48小时内的主要不良事件发生率仅为1.3%。</li><li>手术后不需要住ICU。</li></ul>所有这些加起来,伊那里的检索设备似乎是一个显而易见的选择。</blockquote></p><p> The company grew first-quarter revenue at 113% year over year, and 18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.</p><p><blockquote>该公司第一季度收入同比增长113%,环比增长18%,2021年第一季度毛利率为91.9%。因此,伊那里的市销率为18,使其成为一只正在出售的成长型股票。</blockquote></p><p> Inari has less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.</p><p><blockquote>Inari在价值38亿美元的美国市场的渗透率不到5%,今年早些时候在欧洲推出的市场也有很大的增长空间。这意味着这家市值45亿美元的公司有很多机会。虽然COVID影响了许多选择性和半选择性程序,但它显然没有减缓伊那里,甚至可能加速其吸收。</blockquote></p><p> <h3><b>Novavax: How high can it go?</b></h3> <b>Taylor Carmichael</b> <b>(Novavax):</b> The vaccine biotech Novavax had an amazing 2020, with its share price running up 2,700% on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.</p><p><blockquote><h3><b>Novavax:能涨到多高?</b></h3><b>泰勒·卡迈克尔</b> <b>(诺瓦瓦克斯):</b>疫苗生物技术公司Novavax在2020年表现出色,由于对其COVID疫苗的乐观情绪,其股价上涨了2700%。虽然该公司尚未申请紧急使用授权,但预计将在本季度申请。2021年迄今为止,该股已上涨60%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e7829d99a76c48579ba01c6e55fe14f\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>NVAX DATA BY YCHARTS.</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCHARTS提供的NVAX数据。</span></p></blockquote></p><p> Positive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.</p><p><blockquote>COVID-19疫苗第三阶段的积极数据导致该股在今年年初飙升,但由于该公司的疫苗上市延迟,股价已经回落。首先,制造疫苗所需的原材料短缺。现在,该公司必须证明其各种合同生产设施将保持所有地点的疫苗质量一致。</blockquote></p><p> Despite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.</p><p><blockquote>尽管存在这些延迟,但长期投资者有理由看涨。制造业正在扩大规模,预计到第三季度末,生产率将达到每月1亿剂,到12月将达到每月1.5亿剂。虽然美国的许多人已经接种了疫苗,但世界其他地方的机会相当大。Novavax已向COVAX(国际疫苗联盟)预售了11亿剂疫苗,并已签约在全球范围内供应数亿剂疫苗。</blockquote></p><p> In the U.S., the Novavax vaccine might primarily be used as a booster shot for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told <i>The New York Times</i>.</p><p><blockquote>在美国,Novavax疫苗可能主要用于已经接种疫苗的人的加强注射。FDA代理首席科学家露丝安娜·博里奥(Luciana Borio)博士表示:“它们可能确实适合加强剂。”从2015年到2017年,告诉<i>纽约时报</i>.</blockquote></p><p> Down the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.</p><p><blockquote>未来,Novavax计划将其新冠疫苗与流感疫苗结合起来,形成一种一次性疗法。虽然COVID的变异速度不如流感,但我们在过去一年中已经看到了几种变异毒株。在未来的几年里,我们很可能需要不止一次接种疫苗。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/\">The Motley Fool</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NARI":"Inari Medical, Inc.","NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124757232","content_text":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfizer might surprise to the upside.\nInari Medical is growing like gangbusters.\nNovavax's vaccine might be an important booster shot as the COVID-19 virus mutates.\n\nCOVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?\nA panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of Pfizer, Inari Medical, Inc., and Novavax.\nIMAGE SOURCE: GETTY IMAGES.\nPfizer: More room to run\nGeorge Budwell (Pfizer): American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with BioNTech SE -- losing steam from a sales perspective starting in 2022.\nBecause of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.\nThere are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company announced that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.\nAlthough the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.\nThe big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.\nWhere is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a dividend-paying big pharma stock.\nInari Medical: Skyrocketing Sales\nPatrick Bafuma (Inari Medical): If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to The New York Times -- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.\nThis seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021, up 130% from the same quarter last year and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according toThe Times, Inari is likely to see an uptick in eligible cases.\nNot to mention the company's results thus far for blood clots in the lung are spectacular:\n\nWith the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.\nThere's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.\nMajor adverse events within 48 hours occur at only a 1.3% rate.\nNo ICU stays are required after the procedure.\n\nAdd it all up, and Inari's retrieval device seems like an obvious choice.\nThe company grew first-quarter revenue at 113% year over year, and 18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.\nInari has less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.\nNovavax: How high can it go?\nTaylor Carmichael (Novavax): The vaccine biotech Novavax had an amazing 2020, with its share price running up 2,700% on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.\nNVAX DATA BY YCHARTS.\nPositive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.\nDespite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.\nIn the U.S., the Novavax vaccine might primarily be used as a booster shot for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told The New York Times.\nDown the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.","news_type":1,"symbols_score_info":{"NARI":0.9,"PFE":0.9,"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":469,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":177659248,"gmtCreate":1627213952984,"gmtModify":1633767124261,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570801892131113","authorIdStr":"3570801892131113"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/177659248","repostId":"1115106146","repostType":4,"isVote":1,"tweetType":1,"viewCount":487,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":322944280,"gmtCreate":1615770070140,"gmtModify":1703492667164,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570801892131113","authorIdStr":"3570801892131113"},"themes":[],"htmlText":"Help like and comment","listText":"Help like and comment","text":"Help like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/322944280","repostId":"1155155337","repostType":4,"isVote":1,"tweetType":1,"viewCount":858,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898897882,"gmtCreate":1628482780746,"gmtModify":1633746800080,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570801892131113","authorIdStr":"3570801892131113"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/898897882","repostId":"2157492988","repostType":4,"isVote":1,"tweetType":1,"viewCount":1861,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":351353639,"gmtCreate":1616567873721,"gmtModify":1634525161366,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570801892131113","authorIdStr":"3570801892131113"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/351353639","repostId":"1129380579","repostType":4,"isVote":1,"tweetType":1,"viewCount":467,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":353209889,"gmtCreate":1616497276841,"gmtModify":1634525533220,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570801892131113","authorIdStr":"3570801892131113"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/353209889","repostId":"2121175991","repostType":4,"isVote":1,"tweetType":1,"viewCount":500,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":349573796,"gmtCreate":1617629762615,"gmtModify":1634297459289,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570801892131113","authorIdStr":"3570801892131113"},"themes":[],"htmlText":"Help like and comment","listText":"Help like and comment","text":"Help like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/349573796","repostId":"1130269034","repostType":4,"isVote":1,"tweetType":1,"viewCount":340,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":357458747,"gmtCreate":1617291331089,"gmtModify":1634521558716,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570801892131113","authorIdStr":"3570801892131113"},"themes":[],"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/357458747","repostId":"1144081100","repostType":4,"repost":{"id":"1144081100","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1617280365,"share":"https://www.laohu8.com/m/news/1144081100?lang=zh_CN&edition=full","pubTime":"2021-04-01 20:32","market":"us","language":"en","title":"US.weekly jobless claims total 719,000, above expected<blockquote>美国每周初请失业金人数总计71.9万人,高于预期</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1144081100","media":"Tiger Newspress","summary":"(April 1) First-time claims for jobless benefits were higher than expected last week, with 719,000 m","content":"<p>(April 1) First-time claims for jobless benefits were higher than expected last week, with 719,000 more workers heading to the unemployment line, the Labor Department reported Thursday.</p><p><blockquote>(4月1日)美国劳工部周四报告称,上周首次申请失业救济人数高于预期,又有71.9万名工人接近失业线。</blockquote></p><p>The total compared to the 675,000 estimate from Dow Jones and was above last week’s downwardly revised 658,000.</p><p><blockquote>与道琼斯估计的675,000人相比,这一总数高于上周向下修正的658,000人。</blockquote></p><p>While the number of weekly claims remains inordinately high by historical means, the trend is falling now that the U.S. economy continues to reopen and close to 3 million Americans receive vacations each day for Covid-19.</p><p><blockquote>虽然从历史角度来看,每周申请失业救济人数仍然过高,但随着美国经济继续重新开放,每天有近300万美国人因Covid-19休假,这一趋势正在下降。</blockquote></p><p>Continuing claims, which run a week behind the headline number, fell by 46,000 to just below 3.8 million.</p><p><blockquote>持续申请失业救济人数比总体数字落后一周,减少了46,000人,略低于380万人。</blockquote></p><p>The report comes a day ahead of the government’s nonfarm payrolls count for March, which is expected to show a gain of 675,000, to follow on February’s 379,000.</p><p><blockquote>该报告是在政府公布3月份非农就业人数的前一天发布的,预计3月份非农就业人数将比2月份的37.9万人增加675,000人。</blockquote></p><p>Along with the efforts to combat the virus, the Biden Administration continues to shovel money to boost an economy that is showing signs of solid growth. The president put forth a $2 trillion spending plan Thursday that will build on more than $5 trillion of stimulus either already spent or announced on programs aimed at pulling the nation out of the crisis slump.</p><p><blockquote>在努力抗击病毒的同时,拜登政府继续投入资金来提振显示出稳健增长迹象的经济。总统周四提出了一项2万亿美元的支出计划,该计划将建立在已经支出或宣布的超过5万亿美元的刺激计划的基础上,旨在使国家摆脱危机衰退。</blockquote></p><p>While the pace of job gains slowed in the early part of the winter, recent indications are that hiring has picked up.</p><p><blockquote>尽管初冬就业增长速度放缓,但最近的迹象表明招聘有所回升。</blockquote></p><p>Payroll processing firm ADP estimated that the companies added 517,000 workers in March, the fastest pace since September. Recent manufacturing reports also show plans ahead for more hiring, and job gains appear to be strongest in the battered hospitality sector, which took the worst of the losses due to social distancing and government-imposed restrictions.</p><p><blockquote>薪资处理公司ADP估计,这些公司3月份增加了517,000名员工,这是自9月份以来的最快速度。最近的制造业报告还显示了未来更多招聘的计划,而遭受重创的酒店业的就业增长似乎最为强劲,由于社交距离和政府施加的限制,该行业遭受的损失最为严重。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US.weekly jobless claims total 719,000, above expected<blockquote>美国每周初请失业金人数总计71.9万人,高于预期</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS.weekly jobless claims total 719,000, above expected<blockquote>美国每周初请失业金人数总计71.9万人,高于预期</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-04-01 20:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(April 1) First-time claims for jobless benefits were higher than expected last week, with 719,000 more workers heading to the unemployment line, the Labor Department reported Thursday.</p><p><blockquote>(4月1日)美国劳工部周四报告称,上周首次申请失业救济人数高于预期,又有71.9万名工人接近失业线。</blockquote></p><p>The total compared to the 675,000 estimate from Dow Jones and was above last week’s downwardly revised 658,000.</p><p><blockquote>与道琼斯估计的675,000人相比,这一总数高于上周向下修正的658,000人。</blockquote></p><p>While the number of weekly claims remains inordinately high by historical means, the trend is falling now that the U.S. economy continues to reopen and close to 3 million Americans receive vacations each day for Covid-19.</p><p><blockquote>虽然从历史角度来看,每周申请失业救济人数仍然过高,但随着美国经济继续重新开放,每天有近300万美国人因Covid-19休假,这一趋势正在下降。</blockquote></p><p>Continuing claims, which run a week behind the headline number, fell by 46,000 to just below 3.8 million.</p><p><blockquote>持续申请失业救济人数比总体数字落后一周,减少了46,000人,略低于380万人。</blockquote></p><p>The report comes a day ahead of the government’s nonfarm payrolls count for March, which is expected to show a gain of 675,000, to follow on February’s 379,000.</p><p><blockquote>该报告是在政府公布3月份非农就业人数的前一天发布的,预计3月份非农就业人数将比2月份的37.9万人增加675,000人。</blockquote></p><p>Along with the efforts to combat the virus, the Biden Administration continues to shovel money to boost an economy that is showing signs of solid growth. The president put forth a $2 trillion spending plan Thursday that will build on more than $5 trillion of stimulus either already spent or announced on programs aimed at pulling the nation out of the crisis slump.</p><p><blockquote>在努力抗击病毒的同时,拜登政府继续投入资金来提振显示出稳健增长迹象的经济。总统周四提出了一项2万亿美元的支出计划,该计划将建立在已经支出或宣布的超过5万亿美元的刺激计划的基础上,旨在使国家摆脱危机衰退。</blockquote></p><p>While the pace of job gains slowed in the early part of the winter, recent indications are that hiring has picked up.</p><p><blockquote>尽管初冬就业增长速度放缓,但最近的迹象表明招聘有所回升。</blockquote></p><p>Payroll processing firm ADP estimated that the companies added 517,000 workers in March, the fastest pace since September. Recent manufacturing reports also show plans ahead for more hiring, and job gains appear to be strongest in the battered hospitality sector, which took the worst of the losses due to social distancing and government-imposed restrictions.</p><p><blockquote>薪资处理公司ADP估计,这些公司3月份增加了517,000名员工,这是自9月份以来的最快速度。最近的制造业报告还显示了未来更多招聘的计划,而遭受重创的酒店业的就业增长似乎最为强劲,由于社交距离和政府施加的限制,该行业遭受的损失最为严重。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite","SPY":"标普500ETF",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144081100","content_text":"(April 1) First-time claims for jobless benefits were higher than expected last week, with 719,000 more workers heading to the unemployment line, the Labor Department reported Thursday.The total compared to the 675,000 estimate from Dow Jones and was above last week’s downwardly revised 658,000.While the number of weekly claims remains inordinately high by historical means, the trend is falling now that the U.S. economy continues to reopen and close to 3 million Americans receive vacations each day for Covid-19.Continuing claims, which run a week behind the headline number, fell by 46,000 to just below 3.8 million.The report comes a day ahead of the government’s nonfarm payrolls count for March, which is expected to show a gain of 675,000, to follow on February’s 379,000.Along with the efforts to combat the virus, the Biden Administration continues to shovel money to boost an economy that is showing signs of solid growth. The president put forth a $2 trillion spending plan Thursday that will build on more than $5 trillion of stimulus either already spent or announced on programs aimed at pulling the nation out of the crisis slump.While the pace of job gains slowed in the early part of the winter, recent indications are that hiring has picked up.Payroll processing firm ADP estimated that the companies added 517,000 workers in March, the fastest pace since September. Recent manufacturing reports also show plans ahead for more hiring, and job gains appear to be strongest in the battered hospitality sector, which took the worst of the losses due to social distancing and government-imposed restrictions.","news_type":1,"symbols_score_info":{".IXIC":0.9,"SPY":0.9,".SPX":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":614,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":325699226,"gmtCreate":1615891763865,"gmtModify":1703494556482,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570801892131113","authorIdStr":"3570801892131113"},"themes":[],"htmlText":"Tech sell-off again?","listText":"Tech sell-off again?","text":"Tech sell-off again?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/325699226","repostId":"1105988154","repostType":4,"isVote":1,"tweetType":1,"viewCount":699,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":838620677,"gmtCreate":1629394927699,"gmtModify":1633685162761,"author":{"id":"3570801892131113","authorId":"3570801892131113","name":"Darious","avatar":"https://static.tigerbbs.com/f7f3f9bc5369bcb8a67290cbf0d93885","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570801892131113","authorIdStr":"3570801892131113"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/838620677","repostId":"1102855434","repostType":4,"isVote":1,"tweetType":1,"viewCount":1475,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}